|
 
 |
| REVIEW ARTICLE |
|
| Year : 2014 | Volume
: 10
| Issue : 4 | Page : 853-858 |
|
An overview of doxorubicin formulations in cancer therapy
Sangeeta Rivankar
Department of Research and Development, Bharat Serums and Vaccines Limited, R and D Centre, Mumbai, Maharashtra, India
| Date of Web Publication | 9-Jan-2015 |
Correspondence Address:
Sangeeta Rivankar
Bharat Serums and Vaccines Limited, R and D Centre, DIL Complex, Near Tatwagyan Vidyapeeth, Ghodbunder Road, Thane West, Mumbai - 400 610, Maharashtra
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0973-1482.139267
The burden of cancer is continuously increasing, and is rapidly becoming a global pandemic. The first liposomal encapsulated anticancer drug which received clinical approval against malignancies including solid tumours, transplantable leukemias and lymphomas was Doxorubicin HCl. This review is aimed at providing an overview of doxorubicin in cancer therapy. Pegylated liposomal doxorubicin has a polyethylene glycol (PEG) layer around doxorubicin-containing liposome as the result of a process known as pegylation. Non-pegylated liposomal doxorubicin (NPLD) was developed to overcome the drawbacks associated with previous formulations. Nudoxa; (NPLD) with its unique drug delivery system offers the benefit of pegylated liposomal doxorubicin without hand foot syndrome as the major side effect. Future studies will be directed towards estimating the costs of treatment with the novel liposomal doxorubicin formulations in order to assess their widespread use and robustness in treating patients with cancer. 阿霉素制剂对肿瘤治疗的综述
摘要
癌症负担不断增加，并迅速成为一个流行性疾病。第一个临床被批准临床应用的是阿霉素脂质体，治疗恶性肿瘤包括实体瘤，白血病和淋巴瘤。本文综述阿霉素对肿瘤的治疗。聚乙二醇脂质体阿霉素的聚乙二醇（PEG）层包裹脂质体阿霉素的过程称为聚乙二醇化。非聚乙二醇脂质体阿霉素（NPLD）的开发是为了克服以前的配方相关的缺陷。nudoxa®（NPLD）以其独特的药物传递系统使聚乙二醇化脂质体阿霉素克服了手足综合征的主要副作用。未来的研究应评估新型脂质体阿霉素制剂治疗的成本，以及在广泛应用中的安全性。
关键词：脂质体，非聚乙二醇化，非聚乙二醇脂质体阿霉素，聚乙二醇化 Keywords: Liposomal, nonpegylated, nudoxa, pegylated
How to cite this article:
Rivankar S. An overview of doxorubicin formulations in cancer therapy. J Can Res Ther 2014;10:853-8 |
| > Introduction | |  |
Cancer is a leading cause of morbidity and mortality worldwide. It is estimated that there will be 13.1 million deaths due to cancer in 2030. [1] Anthracyclines, especially doxorubicin, have been the mainstay of cancer therapy since long. Despite its broad-spectrum antineoplastic activity [Table 1], adverse events [Table 2], particularly cardiotoxicity, has limited the use of conventional doxorubicin in clinical practice. [2] This was especially so in patients with advanced disease requiring dose escalation. [3]
Doxorubicin hydrochloride (HCl) liposomal injection was the first liposomal encapsulated anticancer drug to receive clinical approval and has activity against a number of malignancies including solid tumors, transplantable leukemias, and lymphomas. [4]
Previous clinical studies have focused on the lower toxicity and better tolerability of liposomal anticancer drugs. [4] However, in recent years, research has focused on developing novel liposomal formulations. This review is aimed at providing an overview of doxorubicin in cancer therapy.
| > History of doxorubicin | | |
The quest for anticancer compounds from soil-based microorganisms began in the 1950s. A new strain of Streptomyces peucetius, which produced a bright red pigment, was isolated, and an antibiotic was produced from this bacterium that was found to have good activity against mouse tumors. The new compound was named daunorubicin and was used successfully in the treatment of acute leukemia and lymphoma [5],[6] . However, by 1967, it was recognized that daunorubicin could produce fatal cardiac toxicity. [7]
Researches made genetic modifications to the Streptomyces spp. to produce a compound, Adriamycin, which was later called doxorubicin. Though doxorubicin had a higher therapeutic index cardiotoxicity continued to be a major problem. These compounds have been prototypes for subsequent research and today there are approximately more than 2000 known analogs of doxorubicin.
| > Mechanism of action of doxorubicin | | |
The exact mechanism of action of doxorubicin is complex and still unclear. Doxorubicin interacts with the DNA by intercalation thus, inhibiting macromolecular biosynthesis. [8],[9] This further inhibits the progression of the enzyme topoisomerase II, and relaxes supercoils in DNA for transcription. Doxorubicin stabilizes the topoisomerase II complex after it has broken the DNA chain for replication, preventing the DNA double helix from being resealed and thereby stopping the process of replication [Figure 1]. Another mechanism of doxorubicin HCl is its ability to generate free radicals that induce DNA and cell membrane damage.
| > Doxorubicin in cancer therapy | | |
Doxorubicin is most commonly used to treat cancers of the bladder, breast, stomach, lung, ovaries, thyroid, soft tissue sarcoma, multiple myeloma, and Hodgkin's lymphoma. The commonly used doxorubicin-containing regimens may include Adriamycin, cyclophosphamide (AC), Taxotere, AC, Adriamycin, bleomycin, vinblastine, dacarbazine, bleomycin, etoposide, AC, vincristine, procarbazine, and prednisone, cyclophosphamide, Adriamycin, vincristine, prednisone and 5-fluorouracil, AC. Doxil is mainly used for the treatment of ovarian cancer where it has progressed or recurred after platinum-based chemotherapy, or for the treatment of AIDS-related Kaposi's sarcoma. [10]
| > Cardiotoxicity associated with conventional doxorubicin | | |
The cardiotoxicity associated with conventional doxorubicin is broadly classified as either acute or chronic. [11],[12],[13] It is a major concern during therapy as it may be dose-limiting. Risk factors that may increase the occurrence of cardiotoxicity include previous or current heart disease, extremes in age, race, exposure to irradiation in the mediastinal region and the cumulative dose of doxorubicin received. Patients with acute doxorubicin-induced cardiotoxicity usually present with rhythm disturbances, abnormal electrocardiographic changes, and acute, but reversible, reductions in left-ventricular ejection fraction. In general, these symptoms occur within 24 h of infusion, are self-limiting, and do not appear to increase the risk of future cardiac events. Cardiotoxicity, a consequence of conventional doxorubicin treatment manifests as a chronic complication, which ultimately results in congestive cardiomyopathy. Such toxicity has been shown to correlate with peak plasma doxorubicin concentrations, as well as with the lifetime cumulative dose administered. [14],[15] Historically, cardiomyopathy has rarely been observed with cumulative doses of conventional doxorubicin below 450 mg/m 2 ; however, studies suggest that doxorubicin-induced congestive heart failure (CHF) may occur at lower-doses and with greater frequency than previously noted. [16],[17] Von Hoff et al.[16] reported incidence of conventional doxorubicin-induced CHF of approximately 3% at cumulative dose of 400 mg/m 2 , increasing to 7% at 550 mg/m 2 and to 18% at 700 mg/m 2 .
| > Rationale for the development of novel doxorubicin formulations | | |
Several efforts have been made to improve the toxicity profile of conventional anthracyclines, including the development of novel anthracycline analogs, the use of low-dose, prolonged, continuous infusion schedules; co-administration with the cardioprotective agent dexrazoxane; and the use of liposomal encapsulation technology. [12],[18],[19]
The therapy-limiting toxicity for this drug is cardiomyopathy, which may lead to CHF and death. An approach to ameliorating doxorubicin-related toxicity is to use drug carriers, which engender a change in the pharmacological distribution of the drug, resulting in reduced drug levels in the heart. Examples of these carrier systems include lipid-based (liposome) formulations that effect a beneficial change in doxorubicin. Liposomal encapsulation represents the most successful strategy to date for increasing the therapeutic index of conventional anthracyclines. Liposomal drug-delivery systems have been studied extensively to increase the therapeutic index of chemotherapy. The development of liposomal anthracyclines was based on the rationale that liposomes cannot escape the vascular space in areas with tight capillary junctions (heart muscle) but can leave the circulation in tissues and organs lined with cells that are not tightly joined (tumor cells). [20] Thus, liposomal encapsulation results in the preferential concentration of anthracyclines in tumor tissue, while limiting exposure in those sites most frequently associated with conventional anthracycline toxicity, such as the myocardium.
| > Liposomal formulations of doxorubicin | | |
Due to the side-effects of conventional doxorubicin therapy, a need for development of liposomal formulation with equal efficacy and less side-effects arose. One of the main advantages of using liposomes as a delivery system is that the phospholipids used to form these vesicles are extracted from natural sources such as egg yolks or soybean and hence they are safe in the body. In addition, the degree of saturation of phospholipid bilayer can be modified to alter the drug release rate.
Liposomes, composed of natural phospholipids mixed with varying amounts of cholesterol are removed from circulation by the reticuloendothelial system (RES) within a few minutes to a few hours, subsequent to the acquisition of opsonins from plasma. Because of this short circulation half-life, the use of conventional liposomes has limited clinical applications.
| > Pegylated liposomal formulations of doxorubicin | | |
The fact that some polymers, such as polyethylene glycol (PEG), ganglioside, and cerebroside sulfate are able to inhibit opsonization of the liposomes by plasma proteins and increase the half-life of liposomal drugs has renewed activity in the area of liposomal drug-delivery systems. Prolonged circulation of liposomes has been linked to better therapeutic efficacy of liposomal anthracyclines, possibly related to increased accumulation of drug loaded liposomes in tumor tissue.
A further advancement in this line of treatment was the pegylated-liposomal doxorubicin (such as Doxil® /Caelyx® ), a unique form of liposomal doxorubicin, in which the liposomes were coated with PEG in a process known as pegylation. This prevents drug uptake by the RES, thereby prolonging the circulation time (half-life: 3-4 days [21] vs. 30 h for conventional doxorubicin [22] ) beyond that of conventional liposomes and enabling the drug to remain encapsulated until it reaches the tumor site. [23],[24]
Doxil® is approved by the Food and Drug Administration (FDA) for treatment of ovarian cancer after failure of first line platinum-based chemotherapy and multiple myeloma. Outside the United States, Doxil® is known as Caelyx® and is marketed by Janssen. [25] However, there is some evidence that raises doubts on the benefits of pegylation in cancer treatment. PEG is a large molecule and its presence on the liposomal surface may decrease the interactions of liposomes with cells and impede the entry of liposomes into the tumor tissue. [26] This may possibly reduce the accumulation of liposomal drugs in the tumor tissue. A study assessing the accumulation of liposomal doxorubicin in murine Lewis lung carcinoma showed that benefits with PEG liposomal doxorubicin, such as increased blood levels and circulation time may be of little advantage when compared to maximizing drug accumulation in tumors. [27]
However, pegylated-liposomal doxorubicins cause dose-limiting hand-foot syndrome (HFS) (palmar-plantar erythrodysesthesia) characterized by skin eruptions on the palms of the hand and/or soles of the feet, leading to interruption in therapy by at least 2 weeks and decrease in subsequent dosage by 25% (Doxil Product Information Leaflet). The incidence of HFS has been observed in approximately 50% of patients dosed at 50 mg/m 2 (Doxil Product Information leaflet).
Though Caelyx® /Doxil® (pegylated liposomal doxorubicin) has high affinity for the skin and a very long circulation time, a major limitation is dose-limiting HFS (palmar-plantar erythrodysesthesia). [28]
| > Nonpegylated liposomal formulations of doxorubicin | | |
There remains a need for stable, long circulating liposomes that do not cause such deleterious effects such as the HFS. The new variant of liposomal doxorubicin, nonpegylated liposomal doxorubicin (NPLD), has a unique drug-delivery system, and provides a breakthrough in cancer therapy by offering the benefits of pegylated-liposomal doxorubicin without its major side-effects such as HFS.
Nonpegylated liposomal doxorubicin injection provides a better safety profile than not only conventional doxorubicin, but also Doxil® /Caelyx® . NPLD not only reduces the cardiac toxicity associated with doxorubicin, but also the dose-limiting toxicity associated with the use of Doxil® /Caelyx® , such as HFS. This is achieved by a combination of (1) specific composition and (2) a unique manufacturing process (both which have been patented) of the NPLD's liposome, which gives it the desired physicochemical properties.
The NPLDs have an increased circulation time and less cardiotoxicity as compared with conventional doxorubicin. Since NPLDs do not have PEG coating, they are not associated with the painful HFS, which is a dose-limiting adverse event with PEG-doxorubicin.
Myocet® is a NPLD manufactured by Enzon Pharmaceuticals for Cephalon in Europe and for Sopherion Therapeutics in the United States and Canada. [29] Myocet® is approved in Europe and Canada for treatment of metastatic breast cancer in combination with cyclophosphamide. [30] However, it is under the process for the US FDA approval. Three Phase III trials in breast cancer evaluated Myocet® in comparison with standard doxorubicin and epirubicin. Compared to standard doxorubicin, Myocet® demonstrated less cardiotoxicity with no loss of efficacy. Equal doses of epirubicin and Myocet® were as effective with no significant difference in cardiotoxicity. Another limitation of Myocet® is related to its administration which is presented as a three-vial system; Myocet doxorubicin HCl, Myocet liposomes and Myocet buffer. In addition, a small amount of 0.9% sodium chloride for injection is needed, which is not provided in the package. The constituted product is a liposome-encapsulated doxorubicin-citrate complex. [31] Further, the high cost of Myocet® has been a hindrance in its widespread use. This has been a limitation in its robust assessment within the treatment pathway for advanced cancers.
Nudoxa® (NPLD) with its unique drug-delivery system is a breakthrough in cancer therapy as it offers the benefit of pegylated liposomal doxorubicin without its major side-effects like HFS. Further, it decreased the toxicity and other adverse events such as nausea, vomiting, and alopecia. Nudoxa® was jointly developed by Zydus and Bharat Serums and Vaccines Pvt. Limited Nudoxa® is being used as a chemotherapy drug to treat various cancers, such as breast cancer, ovarian cancer, and AIDS-related Kaposi sarcoma. The formulation uses distearoyl-phosphatidylcholine, a phospholipid with high phase transition temperature, which increases the retention of the liposomal content. This allows the doxorubicin HCl liposomes to circulate for prolonged periods in the bloodstream. Liposomes are small enough (average diameter of approximately 100 nm) to pass intact (extravasate) through the defective blood vessels present in the tumors. The liposomal covering helps the drug from escaping into the body's immune system thereby enabling the drug to reach malignant cells. This results in reduction of harmful side-effects owing to minimized distribution of the drug to nontargeted tissues. The preclinical studies were aimed at comparing Nudoxa® with PEG liposomal doxorubicin and conventional doxorubicin (data on file). Nudoxa® has demonstrated favorable toxicity profile in animal models. Further, it offers an advantage over pegylated liposomal doxorubicin due to the absence of HFS. Maximum tolerated dose for Nudoxa® has been established at 70 mg/m 2 in Phase I clinical trials (data on file).
Nudoxa® was launched in the Indian market in 2008 and is being used as a chemotherapy drug to treat various cancers, particularly, breast cancer, ovarian cancer and AIDS-related Kaposi sarcoma. A Phase II/III open label multicentric randomized trial determined the safety and efficacy of Nudoxa® at two different dose levels as compared to doxorubicin in patients with metastatic breast cancer. The trial reported that Nudoxa® at 70 mg/m 2 was as efficacious as conventional doxorubicin with a better safety profile (CTRI/2009/091/1000795).
| > Other novel formulations of doxorubicin | | |
Stealth liposomes have gained an important place in cancer chemotherapy, but still these liposomes are modulated in terms of their selectivity for tumors by attachment of ligands. [32] Antibody coated liposome (immunoliposomes) are extensively studied where either an antibody is attached directly to liposome phospholipid head group or to the terminus of PEG polymer. [33] Temperature sensitive liposomes are also fabricated for tumor targeting. Similarly, acid triggered, enzyme triggered and light triggered release are being studied for delivery of doxorubicin. Other case of active targeting are sulfatide-mediated liposome [34] and folate receptor targeting. [35] Block co-polymers of poly (ethylene oxide)-poly (propylene oxide) block copolymers (pluronics) have also being developed for doxorubicin. Hydroxyapatite implants containing doxorubicin have been developed and tested in in vivo model for osteogenic sarcoma. [36] Thermosensitive poly (organophosphazenes) hydrogels containing doxorubicin have also been studied. The release of loaded doxorubicin from the polymer hydrogel was significantly sustained over 20 days. Oral delivery of microgels composed of pluronics was found to be active against Caco-2 cells. [37] Biological particles like resealed erythrocytes and bacterial ghosts are being explored for the delivery of doxorubicin are also proving to be quite effective. [38] Nanoparticles prepared using polybutylcyanoacrylate as delivery system for doxorubicin to target liver cancer have been studied. [39] The findings suggested that drug was released slowly in liver during detection period in treatment groups. Nanoparticles in range of 100-150 nm diameter range had the best liver targeting characteristics. It also decreased doxorubicin distribution in other tissues such as heart, kidney, and lung. Poly (butylcyanoacrylate) nanoparticles coated with polysorbate 80 considerably enhance the antitumor effect of doxorubicin against an intracranial glioblastoma in rats. [40]
Doxorubicin-loaded polymer-lipid hybrid nanoparticles were formulated and evaluated in a murine solid tumor model. [41] A new bioadhesive drug-delivery system, poly (d, l-lactide-co-glycolide/montmorillonite nanoparticles were developed for oral delivery of paclitaxel. Such a novel formulation is expected to possess extended residence time in the gastrointestinal tract, which promotes oral delivery of paclitaxel. [42]
Among the novel formulations, only the liposomal doxorubicin formulations have been extensively studied and explored in clinical trials in patients with different stages of cancer.
| > Conclusion | | |
Conventional doxorubicin has been a mainstay of treatment for breast and ovarian cancers. Although the use of conventional doxorubicin has been somewhat limited by its adverse effects, recent efforts have markedly improved its safety and tolerability. Until date, the most successful strategy for improving the therapeutic index of conventional doxorubicin formulations has been liposomal encapsulation, which results in preferential accumulation of drug within the tumor site to maximize efficacy and minimize toxicity. Pegylated liposomal doxorubicin has demonstrated efficacy in ovarian cancer patients who have failed platinum and paclitaxel therapies, as well as in metastatic breast cancer. However, dose-limiting HFS limits its usage. Nudoxa® is a NPLD, in which doxorubicin is confined in nonpegylated liposomes. Safety and efficacy of Nudoxa® has been established in several preclinical studies (data on file). Currently Nudoxa® is being studied in clinical trials to establish its safety and efficacy in different types of cancers. The early results show that Nudoxa® is as efficacious as conventional doxorubicin with a better safety profile. This may present an improved treatment regimen for late stage cancer patients.
With established efficacy and safety profiles, future studies will hopefully be directed toward estimating the costs of treatment with the novel liposomal doxorubicin formulations in order to assess their widespread use and robustness in treating patients with cancer.
| > References | | |
| 1. | |
| 2. | Thigpen JT. Innovations in anthracycline therapy: Overview. Commun Oncol 2005;2:3-7.  |
| 3. | Theodoulou M, Hudis C. Cardiac profiles of liposomal anthracyclines: Greater cardiac safety versus conventional doxorubicin? Cancer 2004;100:2052-63. |
| 4. | Slingerland M, Guchelaar HJ, Gelderblom H. Liposomal drug formulations in cancer therapy: 15 years along the road. Drug Discov Today 2012;17:160-6. |
| 5. | Brockmann H. Anthracyclinones and anthracyclines. (Rhodomycinone, pyrromycinone and their glycosides). Fortschr Chem Org Naturst 1963;21:121-82. |
| 6. | Arcamone F, Cassinelli G, Fantini G, Grein A, Orezzi P, Pol C, et al. Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius. Biotechnol Bioeng 1969;11:1101-10. |
| 7. | |
| 8. | Fornari FA, Randolph JK, Yalowich JC, Ritke MK, Gewirtz DA. Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol Pharmacol 1994;45:649-56. |
| 9. | Momparler RL, Karon M, Siegel SE, Avila F. Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells. Cancer Res 1976;36:2891-5. |
| 10. | |
| 11. | Balmer C, Valley AW. Basic principles of cancer treatment and cancer chemotherapy. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors. Pharmacotherapy: A Pathophysiologic Approach. 3 rd ed. Stamford, Conn: Appleton and Lange; 1997. p. 2403-65. |
| 12. | Waterhouse DN, Tardi PG, Mayer LD, Bally MB. A comparison of liposomal formulations of doxorubicin with drug administered in free form: Changing toxicity profiles. Drug Saf 2001;24:903-20. |
| 13. | Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: Incidence, treatment and prevention. Drug Saf 2000;22:263-302. |
| 14. | Maluf FC, Spriggs D. Anthracyclines in the treatment of gynecologic malignancies. Gynecol Oncol 2002;85:18-31. |
| 15. | Hortobágyi GN. Anthracyclines in the treatment of cancer. An overview. Drugs 1997;54:1-7. |
| 16. | Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710-7. |
| 17. | Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer 2003;97:2869-79. |
| 18. | Birtle AJ. Anthracyclines and cardiotoxicity. Clin Oncol (R Coll Radiol) 2000;12:146-52. |
| 19. | Seymour L, Bramwell V, Moran LA. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group. Cancer Prev Control 1999;3:145-59. |
| 20. | Tardi PG, Boman NL, Cullis PR. Liposomal doxorubicin. J Drug Target 1996;4:129-40. |
| 21. | Hilger RA, Richly H, Grubert M, Oberhoff C, Strumberg D, Scheulen ME, et al. Pharmacokinetics (PK) of a liposomal encapsulated fraction containing doxorubicin and of doxorubicin released from the liposomal capsule after intravenous infusion of Caelyx/Doxil. Int J Clin Pharmacol Ther 2005;43:588-9. |
| 22. | Twelves CJ, Dobbs NA, Aldhous M, Harper PG, Rubens RD, Richards MA. Comparative pharmacokinetics of doxorubicin given by three different schedules with equal dose intensity in patients with breast cancer. Cancer Chemother Pharmacol 1991;28:302-7. |
| 23. | Gabizon A, Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs 1997;54 Suppl 4:15-21. |
| 24. | Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994;54:987-92. |
| 25. | |
| 26. | Hong RL, Huang CJ, Tseng YL, Pang VF, Chen ST, Liu JJ, et al. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: Is surface coating with polyethylene glycol beneficial? Clin Cancer Res 1999;5:3645-52. |
| 27. | Parr MJ, Masin D, Cullis PR, Bally MB. Accumulation of liposomal lipid and encapsulated doxorubicin in murine lewis lung carcinoma: The lack of beneficial effects by coating liposomes with poly (ethylene glycol). J Pharmacol Exp Ther 1997;280:1319-27. |
| 28. | Park JW. Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res 2002;4:95-9. |
| 29. | |
| 30. | |
| 31. | |
| 32. | Immordino ML, Dosio F, Cattel L. Stealth liposomes: Review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine 2006;1:297-315. |
| 33. | Schnyder A, Huwyler J. Drug transport to brain with targeted liposomes. NeuroR×2005;2:99-107. |
| 34. | Shao K, Hou Q, Duan W, Go ML, Wong KP, Li QT. Intracellular drug delivery by sulfatide-mediated liposomes to gliomas. J Control Release 2006;115:150-7. |
| 35. | Saul JM, Annapragada A, Natarajan JV, Bellamkonda RV. Controlled targeting of liposomal doxorubicin via the folate receptor in vitro. J Control Release 2003;92:49-67. |
| 36. | Itokazu M, Kumazawa S, Wada E, Wenyi Y. Sustained release of adriamycin from implanted hydroxyapatite blocks for the treatment of experimental osteogenic sarcoma in mice. Cancer Lett 1996;107:11-8. |
| 37. | Bromberg L, Alakhov V. Effects of polyether-modified poly (acrylic acid) microgels on doxorubicin transport in human intestinal epithelial Caco-2 cell layers. J Control Release 2003;88:11-22. |
| 38. | Zocchi E, Tonetti M, Polvani C, Guida L, Benatti U, De Flora A. Encapsulation of doxorubicin in liver-targeted erythrocytes increases the therapeutic index of the drug in a murine metastatic model. Proc Natl Acad Sci U S A 1989;86:2040-4. |
| 39. | Olivier JC. Drug transport to brain with targeted nanoparticles. NeuroRx 2005;2:108-19. |
| 40. | Petri B, Bootz A, Khalansky A, Hekmatara T, Müller R, Uhl R, et al. Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly (butyl cyanoacrylate) nanoparticles: Revisiting the role of surfactants. J Control Release 2007;117:51-8. |
| 41. | Wong HL, Rauth AM, Bendayan R, Wu XY. In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model. Eur J Pharm Biopharm 2007;65:300-8. |
| 42. | Dong Y, Feng SS. Poly (d, l-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs. Biomaterials 2005;26:6068-76. |
[Figure 1]
[Table 1], [Table 2]
| This article has been cited by | | 1 |
Drug-Loaded Mucoadhesive Patch with Active Delivery and Controlled Releasing Ability |
|
| Jihun Lee, Dong-in Kim, Seungmin Bang, Sukho Park | | Advanced Intelligent Systems. 2022; : 2100203 | | [Pubmed] | [DOI] | | | 2 |
Preclinical studies of the antitumor effect of curcumin-loaded polymeric nanocapsules: A systematic review and meta-analysis |
|
| Thayse V. de Oliveira, Renan Stein, Diego F. de Andrade, Ruy C. R. Beck | | Phytotherapy Research. 2022; | | [Pubmed] | [DOI] | | | 3 |
Morin Inhibits Dox-Induced Vascular Inflammation By Regulating PTEN/AKT/NF-?B Pathway |
|
| Jing Yu, Hai-Liang Qi, Hong Zhang, Zi-Yu Zhao, Jing-Zhao, Zi-Yuan Nie | | Inflammation. 2022; | | [Pubmed] | [DOI] | | | 4 |
Circ-LTBP1 is involved in doxorubicin-induced intracellular toxicity in cardiomyocytes via miR-107/ADCY1 signal |
|
| Chunxia Li, Lihui Zhang, Xingpeng Bu, Jinyu Wang, Li Li, Zhiming Yang | | Molecular and Cellular Biochemistry. 2022; | | [Pubmed] | [DOI] | | | 5 |
Molecular relation between biological stress and carcinogenesis |
|
| Katarzyna Rakoczy, Wojciech Szlasa, Natalia Sauer, Jolanta Saczko, Julita Kulbacka | | Molecular Biology Reports. 2022; | | [Pubmed] | [DOI] | | | 6 |
Hepatoprotective potential of the n-butanol extract of Moricandia arvensis from Algeria against doxorubicin induced toxicity in Wistar albino rats |
|
| Meriem Laraba, Sana Hazar Tachour, Hanene Belbache, Nassima Boubekri, Radja Djebbari, Fadila Benayache, Samir Benayache, Djamila Zama | | Advances in Traditional Medicine. 2022; | | [Pubmed] | [DOI] | | | 7 |
Melatonin as an adjuvant treatment modality with doxorubicin |
|
| Parisa Maleki Dana, Fatemeh Sadoughi, Russel J. Reiter, Sotoudeh Mohammadi, Zahra Heidar, Masoumeh Mirzamoradi, Zatollah Asemi | | Biochimie. 2022; | | [Pubmed] | [DOI] | | | 8 |
Melatonin as an adjuvant treatment modality with doxorubicin |
|
| Parisa Maleki Dana, Fatemeh Sadoughi, Russel J.Reiter, Sotoudeh Mohammadi, Zahra Heidar, Masoumeh Mirzamoradi, Zatollah Asemi | | Biochimie. 2022; | | [Pubmed] | [DOI] | | | 9 |
Dosimetric assessment of antitumor treatment by enhanced bleomycin delivery via electroporation and sonoporation |
|
| Martynas Maciulevicius, Mindaugas Tamošiunas, Rytis Jurkonis, Saulius Šatkauskas | | Bioelectrochemistry. 2022; 146: 108153 | | [Pubmed] | [DOI] | | | 10 |
Targeted liposomes for combined delivery of artesunate and temozolomide to resistant glioblastoma |
|
| Muhammad Ismail, Wen Yang, Yanfei Li, Tianran Chai, Dongya Zhang, Qiuli Du, Pir Muhammad, Sumaira Hanif, Meng Zheng, Bingyang Shi | | Biomaterials. 2022; : 121608 | | [Pubmed] | [DOI] | | | 11 |
Heterocyclic Ring Expansion Yields Anthraquinone Derivatives Potent Against Multidrug Resistant Tumor Cells |
|
| Alexander S. Tikhomirov, Vladimir B. Tsvetkov, Yulia L. Volodina, Valeria A. Litvinova, Daria V. Andreeva, Lyubov G. Dezhenkova, Dmitry N. Kaluzhny, Ivan D. Treshalin, Alexander A. Shtil, Andrey E. Shchekotikhin | | Bioorganic Chemistry. 2022; : 105925 | | [Pubmed] | [DOI] | | | 12 |
Establishment of childhood hepatoblastoma xenografts and evaluation of the anti-tumour effects of anlotinib, oxaliplatin and sorafenib |
|
| Dou Yang, Feng Chen, Dan Gong, Lei Zeng, Deng Xiang, Yuanqiao He, Leifeng Chen, Jinlong Yan, Shouhua Zhang | | Pediatric Surgery International. 2022; | | [Pubmed] | [DOI] | | | 13 |
Doxorubicin delivery systems with an acetylacetone-based block in cholesterol-terminated copolymers: diverse activity against estrogen-dependent and estrogen-independent breast cancer cells |
|
| Pawel Misiak, Katarzyna Niemirowicz-Laskowska, Iwona Misztalewska-Turkowicz, Karolina H. Markiewicz, Przemyslaw Wielgat, Halina Car, Agnieszka Z. Wilczewska | | Chemistry and Physics of Lipids. 2022; : 105194 | | [Pubmed] | [DOI] | | | 14 |
Characterization of Caerulomycin A as a dual-targeting anticancer agent |
|
| Lingying Tong, Weichao Sun, Shiyong Wu, Yong Han | | European Journal of Pharmacology. 2022; 922: 174914 | | [Pubmed] | [DOI] | | | 15 |
Bioequivalence of a hybrid pegylated liposomal doxorubicin hydrochloride injection and Caelyx®: A single-dose, randomized, multicenter, open-label, two-period crossover study in patients with advanced ovarian cancer |
|
| S.S. Prakash, Rajnish Vasant Nagarkar, Krishna Chaitanya Puligundla, K.N. Lokesh, Rakesh Reddy Boya, Ankit Baldevbhai Patel, Lovenish Goyal, Aniket Thoke, Jigar Gordhanbhai Patel, Ajay Omprakash Mehta, Ghanshyam Nanubhai Patel, Mujtaba A. Khan, Imran Ahmad | | European Journal of Pharmaceutical Sciences. 2022; : 106248 | | [Pubmed] | [DOI] | | | 16 |
Oleanolic Acid-conjugated human serum albumin nanoparticles encapsulating doxorubicin as synergistic combination chemotherapy in oropharyngeal carcinoma and melanoma |
|
| Soniya Kumbham, Milan Paul, Asif Itoo, Balaram Ghosh, Swati Biswas | | International Journal of Pharmaceutics. 2022; : 121479 | | [Pubmed] | [DOI] | | | 17 |
Dual-targeted and controlled release delivery of doxorubicin to breast adenocarcinoma: In vitro and in vivo studies |
|
| Zahra Jamshidi, Taraneh Sadat Zavvar, Mohammad Ramezani, Mona Alibolandi, Farzin Hadizadeh, Khalil Abnous, Seyed Mohammad Taghdisi | | International Journal of Pharmaceutics. 2022; : 121892 | | [Pubmed] | [DOI] | | | 18 |
Design and optimization of PEGylated silver nanoparticles for efficient delivery of doxorubicin to cancer cells |
|
| Ahmed Abdelfattah, Ahmed E. Aboutaleb, Abu-Baker M. Abdel-Aal, Ahmed A.H. Abdellatif, Hesham M. Tawfeek, Sayed I. Abdel-Rahman | | Journal of Drug Delivery Science and Technology. 2022; : 103347 | | [Pubmed] | [DOI] | | | 19 |
Free- and liposomal- doxorubicin delivery via microbubble inertial cavitation |
|
| Martynas Maciulevicius, Mindaugas Tamošiunas, Diana Navickaite, Saulius Šatkauskas, Mindaugas S. Venslauskas | | Journal of Drug Delivery Science and Technology. 2022; : 103386 | | [Pubmed] | [DOI] | | | 20 |
Hydrazone modified nanoscale metal-organic frameworks as pH responsive nanoplatforms for cancer therapy |
|
| Datian Fu, Yan Wang, Jin Xu, Haimei Wu | | Journal of Solid State Chemistry. 2022; 310: 123029 | | [Pubmed] | [DOI] | | | 21 |
Protective effects of berberine on various kidney diseases: Emphasis on the promising effects and the underlined molecular mechanisms |
|
| Emad H.M. Hassanein, Islam M. Ibrahim, Esraa K. Abd-alhameed, Nesma M. Mohamed, Samir A. Ross | | Life Sciences. 2022; : 120697 | | [Pubmed] | [DOI] | | | 22 |
Doxorubicin-induced senescence in normal fibroblasts promotes in vitro tumour cell growth and invasiveness: the role of Quercetin in modulating these processes |
|
| Elisa Bientinesi, Matteo Lulli, Matteo Becatti, Sara Ristori, Francesca Margheri, Daniela Monti | | Mechanisms of Ageing and Development. 2022; : 111689 | | [Pubmed] | [DOI] | | | 23 |
Apocynum venetum leaf extract alleviated doxorubicin-induced cardiotoxicity through the AKT/Bcl-2 signaling pathway |
|
| Yang Zhang, Shan Liu, Jiu-Long Ma, Chen Chen, Peng Huang, Jia-Hua Ji, Di Wu, Li-Qun Ren | | Phytomedicine. 2022; 94: 153815 | | [Pubmed] | [DOI] | | | 24 |
Greenness estimation of chromatographic assay for the determination of anthracycline-based antitumor drug in bacterial ghost matrix of Salmonella typhimurium |
|
| Nazrul Haq, Fars K. Alanazi, Mounir M. Salem-Bekhit, Sameh Rabea, Prawez Alam, Ibrahim A. Alsarra, Faiyaz Shakeel | | Sustainable Chemistry and Pharmacy. 2022; 26: 100642 | | [Pubmed] | [DOI] | | | 25 |
Benefits and limitations of nanomedicine treatment of brain cancers and age-dependent neurodegenerative disorders |
|
| Margarita E. Neganova, Yulia R. Aleksandrova, Olga A. Sukocheva, Sergey G. Klochkov | | Seminars in Cancer Biology. 2022; | | [Pubmed] | [DOI] | | | 26 |
Engineering Chemotherapeutic-Augmented Calcium Phosphate Nanoparticles for Treatment of Intraperitoneal Disseminated Ovarian Cancer |
|
| Miaojuan Qiu, Junzong Chen, Xiuyu Huang, Binbin Li, Shiqiang Zhang, Peng Liu, Qiang Wang, Zhi Rong Qian, Yihang Pan, Yu Chen, Jing Zhao | | ACS Applied Materials & Interfaces. 2022; | | [Pubmed] | [DOI] | | | 27 |
NUIG4: A biocompatible pcu metal–organic framework with an exceptional doxorubicin encapsulation capacity |
|
| Ahmed Ahmed, Constantinos G. Efthymiou, Rana Sanii, Ewa Patyk-Kazmierczak, Amir M. Alsharabasy, Meghan Winterlich, Naveen Kumar, Debobroto Sensharma, Wenming Tong, Sarah Guerin, Pau Farras, Sarah Hudson, Damien Thompson, Michael J. Zaworotko, Anastasios J. Tasiopoulos, Constantina Papatriantafyllopoulou | | Journal of Materials Chemistry B. 2022; | | [Pubmed] | [DOI] | | | 28 |
Current Insights into Cellular Senescence and Myotoxicity Induced by
Doxorubicin: The Role of Exercise and Growth Factors |
|
| Charalampos Andreou, Antonios Matsakas | | International Journal of Sports Medicine. 2022; | | [Pubmed] | [DOI] | | | 29 |
Bixin Prevents Colorectal Cancer Development through AMPK-Activated Endoplasmic Reticulum Stress |
|
| Yunfeng Qiu, Changfeng Li, Bin Zhang, Yue Gu | | BioMed Research International. 2022; 2022: 1 | | [Pubmed] | [DOI] | | | 30 |
Progress in drug-delivery systems in cardiovascular applications: stents, balloons and nanoencapsulation |
|
| Jaryl Chen Koon Ng, Daniel Wee Yee Toong, Valerie Ow, Su Yin Chaw, Hanwei Toh, Philip En Hou Wong, Subbu Venkatraman, Tze Tec Chong, Lay Poh Tan, Ying Ying Huang, Hui Ying Ang | | Nanomedicine. 2022; | | [Pubmed] | [DOI] | | | 31 |
A Review of Pharmacology, Toxicity and Pharmacokinetics of 2,3,5,4'-Tetrahydroxystilbene-2-O-ß-D-Glucoside |
|
| Cheng Wang, Shu Dai, Lihong Gong, Ke Fu, Cheng Ma, Yanfang Liu, Honglin Zhou, Yunxia Li | | Frontiers in Pharmacology. 2022; 12 | | [Pubmed] | [DOI] | | | 32 |
Thioredoxin-1 Activation by Pterostilbene Protects Against Doxorubicin-Induced Hepatotoxicity via Inhibiting the NLRP3 Inflammasome |
|
| Shiqing Tan, Jie Bai, Mingxi Xu, Longying Zhang, Ying Wang | | Frontiers in Pharmacology. 2022; 13 | | [Pubmed] | [DOI] | | | 33 |
Cariporide Attenuates Doxorubicin-Induced Cardiotoxicity in Rats by Inhibiting Oxidative Stress, Inflammation and Apoptosis Partly Through Regulation of Akt/GSK-3ß and Sirt1 Signaling Pathway |
|
| Wenli Liao, Zhiwei Rao, Lingling Wu, Yong Chen, Cairong Li | | Frontiers in Pharmacology. 2022; 13 | | [Pubmed] | [DOI] | | | 34 |
Long Non-Coding RNA in Gastric Cancer: Mechanisms and Clinical Implications for Drug Resistance |
|
| Ying Liu, Xiang Ao, Yu Wang, Xiaoge Li, Jianxun Wang | | Frontiers in Oncology. 2022; 12 | | [Pubmed] | [DOI] | | | 35 |
Smart Lipid–Polysaccharide Nanoparticles for Targeted Delivery of Doxorubicin to Breast Cancer Cells |
|
| Manuela Curcio, Matteo Brindisi, Giuseppe Cirillo, Luca Frattaruolo, Antonella Leggio, Vittoria Rago, Fiore Pasquale Nicoletta, Anna Rita Cappello, Francesca Iemma | | International Journal of Molecular Sciences. 2022; 23(4): 2386 | | [Pubmed] | [DOI] | | | 36 |
Nanoliposomes in Cancer Therapy: Marketed Products and Current Clinical Trials |
|
| Raquel Taléns-Visconti, Octavio Díez-Sales, Jesus Vicente de Julián-Ortiz, Amparo Nácher | | International Journal of Molecular Sciences. 2022; 23(8): 4249 | | [Pubmed] | [DOI] | | | 37 |
Impact of Doxorubicin on Cell-Substrate Topology |
|
| Andreas Krecsir, Verena Richter, Michael Wagner, Herbert Schneckenburger | | International Journal of Molecular Sciences. 2022; 23(11): 6277 | | [Pubmed] | [DOI] | | | 38 |
Design and Synthesis of Menthol and Thymol Derived Ciprofloxacin: Influence of Structural Modifications on the Antibacterial Activity and Anticancer Properties |
|
| Tomasz Szostek, Daniel Szulczyk, Jolanta Szymanska-Majchrzak, Michal Kolinski, Sebastian Kmiecik, Dagmara Otto-Slusarczyk, Aleksandra Zawodnik, Eliza Rajkowska, Kinga Chaniewicz, Marta Struga, Piotr Roszkowski | | International Journal of Molecular Sciences. 2022; 23(12): 6600 | | [Pubmed] | [DOI] | | | 39 |
The Mechanism of Dynamic Interaction between Doxorubicin and Calf Thymus DNA at the Single-Molecule Level Based on Confocal Raman Spectroscopy |
|
| Ruihong Zhang, Jie Zhu, Dan Sun, Jie Li, Lina Yao, Shuangshuang Meng, Yan Li, Yang Dang, Kaige Wang | | Micromachines. 2022; 13(6): 940 | | [Pubmed] | [DOI] | | | 40 |
Targeted Drug Delivery Biopolymers Effectively Inhibit Breast Tumor Growth and Prevent Doxorubicin-Induced Cardiotoxicity |
|
| Sonja Dragojevic, Jung Su Ryu, Michael E. Hall, Drazen Raucher | | Molecules. 2022; 27(11): 3371 | | [Pubmed] | [DOI] | | | 41 |
Synthesis of a new water-soluble hexacarboxylated tribenzotriquinacene derivative and its competitive host–guest interaction for drug delivery |
|
| Man-Ping Li, Nan Yang, Wen-Rong Xu | | Beilstein Journal of Organic Chemistry. 2022; 18: 539 | | [Pubmed] | [DOI] | | | 42 |
Dual-Targeted Hyaluronic Acid/Albumin Micelle-Like Nanoparticles for the Vectorization of Doxorubicin |
|
| Manuela Curcio, Luis Diaz-Gomez, Giuseppe Cirillo, Fiore Pasquale Nicoletta, Antonella Leggio, Francesca Iemma | | Pharmaceutics. 2021; 13(3): 304 | | [Pubmed] | [DOI] | | | 43 |
Os Efeitos da Doxorrubicina na Biossíntese e no Metabolismo do Heme em Cardiomiócitos |
|
| Zuoyan Wang, Junyi Gao, Haobo Teng, Jianjun Peng | | Arquivos Brasileiros de Cardiologia. 2021; 116(2): 315 | | [Pubmed] | [DOI] | | | 44 |
Role of Creatine in the Heart: Health and Disease |
|
| Maurizio Balestrino | | Nutrients. 2021; 13(4): 1215 | | [Pubmed] | [DOI] | | | 45 |
The Effects of Bergamot Polyphenolic Fraction, Cynara cardunculus, and Olea europea L. Extract on Doxorubicin-Induced Cardiotoxicity |
|
| Jessica Maiuolo, Irene Bava, Cristina Carresi, Micaela Gliozzi, Vincenzo Musolino, Federica Scarano, Saverio Nucera, Miriam Scicchitano, Francesca Bosco, Stefano Ruga, Maria Caterina Zito, Francesca Oppedisano, Roberta Macri, Annamaria Tavernese, Rocco Mollace, Vincenzo Mollace | | Nutrients. 2021; 13(7): 2158 | | [Pubmed] | [DOI] | | | 46 |
Statin as a Potential Chemotherapeutic Agent: Current Updates as a Monotherapy, Combination Therapy, and Treatment for Anti-Cancer Drug Resistance |
|
| Nirmala Tilija Pun, Chul-Ho Jeong | | Pharmaceuticals. 2021; 14(5): 470 | | [Pubmed] | [DOI] | | | 47 |
Thymoquinone and its nanoformulation attenuate colorectal and breast cancers and alleviate doxorubicin-induced cardiotoxicity |
|
| Ali H El-Far, Taher A Salaheldin, Kavitha Godugu, Noureldien HE Darwish, Shaker A Mousa | | Nanomedicine. 2021; 16(17): 1457 | | [Pubmed] | [DOI] | | | 48 |
Hyperthermia Enhances Doxorubicin Therapeutic Efficacy against A375 and MNT-1 Melanoma Cells |
|
| Diana Salvador, Verónica Bastos, Helena Oliveira | | International Journal of Molecular Sciences. 2021; 23(1): 35 | | [Pubmed] | [DOI] | | | 49 |
Cold Atmospheric Plasma: A New Strategy Based Primarily on Oxidative Stress for Osteosarcoma Therapy |
|
| Miguel Mateu-Sanz, Juan Tornín, Maria-Pau Ginebra, Cristina Canal | | Journal of Clinical Medicine. 2021; 10(4): 893 | | [Pubmed] | [DOI] | | | 50 |
A Review on Drug Delivery System for Tumor Therapy |
|
| Guoxiang Liu, Lina Yang, Guang Chen, Fenghua Xu, Fanghao Yang, Huaxin Yu, Lingne Li, Xiaolei Dong, Jingjing Han, Can Cao, Jingyu Qi, Junzhe Su, Xiaohui Xu, Xiaoxia Li, Bing Li | | Frontiers in Pharmacology. 2021; 12 | | [Pubmed] | [DOI] | | | 51 |
Albumin-Based Nanoparticles for the Delivery of Doxorubicin in Breast Cancer |
|
| Rama Prajapati, Eduardo Garcia-Garrido, Álvaro Somoza | | Cancers. 2021; 13(12): 3011 | | [Pubmed] | [DOI] | | | 52 |
Chemotherapeutic Regimens and Chemotherapy-Free Intervals Influence the Survival of Patients with Recurrent Advanced Epithelial Ovarian Carcinoma: A Retrospective Population-Based Study |
|
| Hsin-Ying Huang, Chun-Ju Chiang, Yun-Yuan Chen, San-Lin You, Heng-Cheng Hsu, Chao-Hsiun Tang, Wen-Fang Cheng | | International Journal of Environmental Research and Public Health. 2021; 18(12): 6629 | | [Pubmed] | [DOI] | | | 53 |
Synergistic Antitumor Activity of Gramicidin/Lipophilic Bismuth Nanoparticles (BisBAL NPs) on Human Cervical Tumor Cells |
|
| Claudio Cabral-Romero, Claudia María García-Cuellar, Rene Hernandez-Delgadillo, Yesennia Sánchez-Pérez, Irene Meester, Juan Manuel Solís-Soto, Nayely Pineda-Aguilar, Shankararaman Chellam | | Frontiers in Nanotechnology. 2021; 3 | | [Pubmed] | [DOI] | | | 54 |
A Novel Strategy Conjugating PD-L1 Polypeptide With Doxorubicin Alleviates Chemotherapeutic Resistance and Enhances Immune Response in Colon Cancer |
|
| Maolin Wang, Xing-sheng Shu, Meiqi Li, Yilin Zhang, Youli Yao, Xiaoyan Huang, Jianna Li, Pengfei Wei, Zhendan He, Jun Lu, Ying Ying | | Frontiers in Oncology. 2021; 11 | | [Pubmed] | [DOI] | | | 55 |
Protective effects and mechanism of coenzyme Q10 and vitamin C on doxorubicin-induced gastric mucosal injury and effects of intestinal flora |
|
| Xiaomeng Zhao, Xueke Feng, Nan Ye, Panpan Wei, Zhanwei Zhang, Wenyu Lu | | The Korean Journal of Physiology & Pharmacology. 2021; 25(4): 261 | | [Pubmed] | [DOI] | | | 56 |
Regulatory role of the transforming growth factor-ß signaling pathway in the drug resistance of gastrointestinal cancers |
|
| Xiaoqun Lv, Guoxiong Xu | | World Journal of Gastrointestinal Oncology. 2021; 13(11): 1648 | | [Pubmed] | [DOI] | | | 57 |
Evaluation of Anti-Cancer Effects of Caspian Cobra (Naja naja oxiana) Snake Venom in Comparison with Doxorubicin in HeLa Cancer Cell Line and Normal HFF Fibroblast |
|
| Fatemeh Javani Jouni, Jaber Zafari, Elaheh Shams, Parviz Abdolmaleki, Ali asghar Rastegari | | journal of ilam university of medical sciences. 2021; 29(6): 20 | | [Pubmed] | [DOI] | | | 58 |
Breast cancer: Muscarinic receptors as new targets for tumor therapy |
|
| Alejandro Español, Agustina Salem, Yamila Sanchez, María Elena Sales | | World Journal of Clinical Oncology. 2021; 12(6): 404 | | [Pubmed] | [DOI] | | | 59 |
Mechanisms and Potential Treatment Options of Heart Failure in Patients With Multiple Myeloma |
|
| Ekaterina Proskuriakova, Keji Jada, Sandrine Kakieu Djossi, Anwar Khedr, Bandana Neupane, Jihan A Mostafa | | Cureus. 2021; | | [Pubmed] | [DOI] | | | 60 |
Cancer—A Major Cardiac Comorbidity With Implications on Cardiovascular Metabolism |
|
| Daniel Finke, Markus B. Heckmann, Norbert Frey, Lorenz H. Lehmann | | Frontiers in Physiology. 2021; 12 | | [Pubmed] | [DOI] | | | 61 |
Diosmin Alleviates Doxorubicin-Induced Liver Injury via Modulation of Oxidative Stress-Mediated Hepatic Inflammation and Apoptosis via NfkB and MAPK Pathway: A Preclinical Study |
|
| Abdullah F. AlAsmari, Metab Alharbi, Faleh Alqahtani, Fawaz Alasmari, Mohammed AlSwayyed, Sami I. Alzarea, Ibrahim A. Al-Alallah, Adel Alghamdi, Hassan M. Hakami, Meshal K. Alyousef, Youssef Sari, Nemat Ali | | Antioxidants. 2021; 10(12): 1998 | | [Pubmed] | [DOI] | | | 62 |
Anthraquinones as Inhibitors of SOS RAS-GEF Activity |
|
| Alberto Fernández-Medarde, Rocío Fuentes-Mateos, Rósula García-Navas, Andrea Olarte-San Juan, José María Sánchez-López, Antonio Fernández-Medarde, Eugenio Santos | | Biomolecules. 2021; 11(8): 1128 | | [Pubmed] | [DOI] | | | 63 |
Nanonutraceuticals: Anti-Cancer Activity and Improved Safety of Chemotherapy by Costunolide and Its Nanoformulation against Colon and Breast Cancer |
|
| Ali H. El-Far, Kavitha Godugu, Taher A. Salaheldin, Noureldien H. E. Darwish, Amna A. Saddiq, Shaker A. Mousa | | Biomedicines. 2021; 9(8): 990 | | [Pubmed] | [DOI] | | | 64 |
Surface PEGylated Cancer Cell Membrane-Coated Nanoparticles for Codelivery of Curcumin and Doxorubicin for the Treatment of Multidrug Resistant Esophageal Carcinoma |
|
| Yi Gao, Yue Zhu, Xiaopeng Xu, Fangjun Wang, Weidong Shen, Xia Leng, Jiyi Zhao, Bingtuan Liu, Yangyun Wang, Pengfei Liu | | Frontiers in Cell and Developmental Biology. 2021; 9 | | [Pubmed] | [DOI] | | | 65 |
Integrative analysis identifies key mRNA biomarkers for diagnosis, prognosis, and therapeutic targets of HCV-associated hepatocellular carcinoma |
|
| Yongqiang Zhang, Yuqin Tang, Chengbin Guo, Gen Li | | Aging. 2021; 13(9): 12865 | | [Pubmed] | [DOI] | | | 66 |
Roflumilast Attenuates Doxorubicin-Induced Cardiotoxicity by Targeting Inflammation and Cellular Senescence in Cardiomyocytes Mediated by SIRT1 |
|
| Sheng Zhang, Peng Wu, Jiabao Liu, Yingqiang Du, Zhijian Yang | | Drug Design, Development and Therapy. 2021; Volume 15: 87 | | [Pubmed] | [DOI] | | | 67 |
ß-Elemene Enhances the Sensitivity of Osteosarcoma Cells to Doxorubicin via Downregulation of Peroxiredoxin-1 |
|
| Shaochun Zhang, Weichun Guo | | OncoTargets and Therapy. 2021; Volume 14: 3599 | | [Pubmed] | [DOI] | | | 68 |
Isoliquiritigenin ameliorates doxorubicin-induced acute pancreatitis by inhibiting ROS production via modulation of Nrf2/HO-1 oxidative stress pathway |
|
| Chen-Chen Yuan, Qing-Tian Zhu, Qin-Hao Shen, Xing-Meng Xu, Yao Xu, Qi Yang, Bai-Qiang Li, Guo-Tao Lu, Wei-Qin Li | | World Chinese Journal of Digestology. 2021; 29(6): 282 | | [Pubmed] | [DOI] | | | 69 |
Immunomodulatory effects of bee pollen on doxorubicin-induced bone marrow/spleen immunosuppression in rat |
|
| Fayez Shaldoum, Attalla F. El-kott, Marwa Mohamed Ahmed Ouda, Eman M. Abd-Ella | | Journal of Food Biochemistry. 2021; 45(6) | | [Pubmed] | [DOI] | | | 70 |
Reduction of doxorubicin-induced cytotoxicity and mitochondrial damage by betanin in rat isolated cardiomyocytes and mitochondria |
|
| AA Hafez, Z Jamali, S Samiei, S Khezri, A Salimi | | Human & Experimental Toxicology. 2021; 40(12): 2123 | | [Pubmed] | [DOI] | | | 71 |
Thymoquinone and Costunolide Induce Apoptosis of Both Proliferative and Doxorubicin-Induced-Senescent Colon and Breast Cancer Cells |
|
| Ali H El-Far, Kavitha Godugu, Ahmed E. Noreldin, Amna A. Saddiq, Omar A. Almaghrabi, Soad K. Al Jaouni, Shaker A. Mousa | | Integrative Cancer Therapies. 2021; 20: 1534735421 | | [Pubmed] | [DOI] | | | 72 |
Platelet-rich plasma inhibits Adriamycin-induced inflammation via blocking the NF-?B pathway in articular chondrocytes |
|
| Haijun Zhao, Weijie Zhu, Wude Mao, Chengkai Shen | | Molecular Medicine. 2021; 27(1) | | [Pubmed] | [DOI] | | | 73 |
A novel formulation of theranostic nanomedicine for targeting drug delivery to gastrointestinal tract cancer |
|
| Madeeha Shahzad Lodhi, Muhammad Tahir Khan, Saira Aftab, Zahoor Qadir Samra, Heng Wang, Dong Qing Wei | | Cancer Nanotechnology. 2021; 12(1) | | [Pubmed] | [DOI] | | | 74 |
Development of an engineered peptide antagonist against periostin to overcome doxorubicin resistance in breast cancer |
|
| Khine Kyaw Oo, Thanpawee Kamolhan, Anish Soni, Suyanee Thongchot, Chalermchai Mitrpant, Pornchai O-charoenrat, Chanitra Thuwajit, Peti Thuwajit | | BMC Cancer. 2021; 21(1) | | [Pubmed] | [DOI] | | | 75 |
Doxorubicin treatment modulates chemoresistance and affects the cell cycle in two canine mammary tumour cell lines |
|
| Michela Levi, Roberta Salaroli, Federico Parenti, Raffaella De Maria, Augusta Zannoni, Chiara Bernardini, Cecilia Gola, Antonio Brocco, Asia Marangio, Cinzia Benazzi, Luisa Vera Muscatello, Barbara Brunetti, Monica Forni, Giuseppe Sarli | | BMC Veterinary Research. 2021; 17(1) | | [Pubmed] | [DOI] | | | 76 |
Hsa_circ_0004674 promotes osteosarcoma doxorubicin resistance by regulating the miR-342-3p/FBN1 axis |
|
| Yumei Bai, Yanghua Li, Juan Bai, Yumei Zhang | | Journal of Orthopaedic Surgery and Research. 2021; 16(1) | | [Pubmed] | [DOI] | | | 77 |
miR-520b Inhibits IGF-1R to Increase Doxorubicin Sensitivity and Promote Cell Apoptosis in Breast Cancer |
|
| Hui Zhang, Xiao-Dong Zheng, Xiao-Hua Zeng, Li Li, Qi Zhou | | YAKUGAKU ZASSHI. 2021; 141(3): 415 | | [Pubmed] | [DOI] | | | 78 |
Evaluation of Cytotoxicity Induced by the Anti-Cancerous Drugs Doxorubicin and Erlotinib in Allium cepa Assay for Eco-Safety Monitoring |
|
| Debadrito Das, Prashanta Kumar Mitra, Sudha Gupta | | CYTOLOGIA. 2021; 86(3): 195 | | [Pubmed] | [DOI] | | | 79 |
Circ-SKA3 Enhances Doxorubicin Toxicity in AC16 Cells Through miR-1303/TLR4 Axis |
|
| Bin Li, Xinyong Cai, Yunxia Wang, Hongmin Zhu, Ping Zhang, Panpan Jiang, Xu Yang, Jianhua Sun, Lang Hong, Liang Shao | | International Heart Journal. 2021; 62(5): 1112 | | [Pubmed] | [DOI] | | | 80 |
Enhanced antitumour efficacy of functionalized doxorubicin plus schisandrin B co-delivery liposomes via inhibiting epithelial-mesenchymal transition |
|
| Fu-Yi Cai, Xue-Min Yao, Ming Jing, Liang Kong, Jing-Jing Liu, Min Fu, Xin-Ze Liu, Lu Zhang, Si-Yu He, Xue-Tao Li, Rui-Jun Ju | | Journal of Liposome Research. 2021; 31(2): 113 | | [Pubmed] | [DOI] | | | 81 |
Loading of doxorubicin on poly(methyl methacrylate-co-methacrylic acid) nanoparticles and release study |
|
| Roberto López-Muñoz, María Esther Treviño, Fabiola Castellanos, Graciela Morales, Oliverio Rodríguez-Fernández, Santiago Saavedra, Angel Licea-Claverie, Hened Saade, Francisco Javier Enríquez-Medrano, Raúl Guillermo López | | Journal of Biomaterials Science, Polymer Edition. 2021; 32(9): 1107 | | [Pubmed] | [DOI] | | | 82 |
Role of miRNAs in regulating responses to radiotherapy in human breast cancer |
|
| Zhi Xiong Chong, Swee Keong Yeap, Wan Yong Ho | | International Journal of Radiation Biology. 2021; 97(3): 289 | | [Pubmed] | [DOI] | | | 83 |
Toxic effects and molecular mechanism of doxorubicin on different organs – an update |
|
| Kaviyarasi Renu, Lakshmi Prasanna Pureti, Balachandar Vellingiri, Abilash Valsala Gopalakrishnan | | Toxin Reviews. 2021; : 1 | | [Pubmed] | [DOI] | | | 84 |
Differential Effects of p-Coumaric Acid in relieving Doxorubicin induced Cardiotoxicity in Solid Tumour Bearing and Non-tumor Bearing Mice |
|
| Sunitha Mary Chacko, R DhanyaKrishnan, Kottayath Govindan Nevin | | Journal of Biologically Active Products from Nature. 2021; 11(2): 138 | | [Pubmed] | [DOI] | | | 85 |
Dual covalent functionalization of single-walled carbon nanotubes for effective targeted cancer therapy |
|
| Mohyeddin Assali, Naim Kittana, Safa’ Dayyeh, Noureddine Khiar | | Nanotechnology. 2021; 32(20): 205101 | | [Pubmed] | [DOI] | | | 86 |
Engineering the early bone metastatic niche through human vascularized immuno bone minitissues |
|
| Maria Vittoria Colombo, Simone Bersini, Chiara Arrigoni, Mara Gilardi, Veronica Sansoni, Enrico Ragni, Gabriele Candiani, Giovanni Lombardi, Matteo Moretti | | Biofabrication. 2021; 13(3): 035036 | | [Pubmed] | [DOI] | | | 87 |
Ozone Attenuated H9c2 Cell Injury Induced by Doxorubicin |
|
| Lingshan Xu, Chenhao Wang, Zhiqing Zou, Zhouquan Wu | | Journal of Cardiovascular Pharmacology. 2021; 78(1): e86 | | [Pubmed] | [DOI] | | | 88 |
The application of aluminium phthalocyanine AlPs-4-mediated photodynamic therapy against human soft tissue sarcoma (RMS) cell line |
|
| Muhammad Zakir, Ahmat Khurshid, Muhammad Iqbal Khan, Asma Khattak, Murad Ali Khan | | Journal of Porphyrins and Phthalocyanines. 2021; 25(02): 102 | | [Pubmed] | [DOI] | | | 89 |
Polyethylenimine–Bisphosphonate–Cyclodextrin Ternary Conjugates: Supramolecular Systems for the Delivery of Antineoplastic Drugs |
|
| Simona Plesselova, Pablo Garcia-Cerezo, Victor Blanco, Francisco J. Reche-Perez, Fernando Hernandez-Mateo, Francisco Santoyo-Gonzalez, María Dolores Giron-Gonzalez, Rafael Salto-Gonzalez | | Journal of Medicinal Chemistry. 2021; 64(16): 12245 | | [Pubmed] | [DOI] | | | 90 |
Thymic function affects breast cancer development and metastasis by regulating expression of thymus secretions PTMa and Tß15b1 |
|
| Dongling Shi, Yanmei Shui, Xie Xu, Kai He, Fengqing Yang, Jianli Gao | | Translational Oncology. 2021; 14(1): 100980 | | [Pubmed] | [DOI] | | | 91 |
Chemotherapeutic drugs: Cell death- and resistance-related signaling pathways. Are they really as smart as the tumor cells? |
|
| Mojtaba Mollaei, Zuhair Mohammad Hassan, Fatemeh Khorshidi, Ladan Langroudi | | Translational Oncology. 2021; 14(5): 101056 | | [Pubmed] | [DOI] | | | 92 |
AIE-Based Fluorescent Triblock Copolymer Micelles for Simultaneous Drug Delivery and Intracellular Imaging |
|
| Bhagyashree Kulkarni, Somayah Qutub, Viko Ladelta, Niveen M. Khashab, Nikos Hadjichristidis | | Biomacromolecules. 2021; | | [Pubmed] | [DOI] | | | 93 |
Miniatured Fluidics-Mediated Modular Self-Assembly of Anticancer Drug–Amino Acid Composite Microbowls for Combined Chemo-Photodynamic Therapy in Glioma |
|
| Sonika Chibh, Vibhav Katoch, Manish Singh, Bhanu Prakash, Jiban Jyoti Panda | | ACS Biomaterials Science & Engineering. 2021; | | [Pubmed] | [DOI] | | | 94 |
?-Ray-Triggered Drug Release of Reactive Oxygen Species-Sensitive Nanomedicine for Enhanced Concurrent Chemoradiation Therapy |
|
| Ying Yu, Zujian Feng, Jinjian Liu, Xiaoxue Hou, Xiaoqian Zhou, Jie Gao, Wei Wang, Yumin Zhang, Guoliang Li, Jianfeng Liu | | ACS Omega. 2021; 6(30): 19445 | | [Pubmed] | [DOI] | | | 95 |
Two-dimensional materials in biomedical, biosensing and sensing applications |
|
| Nasuha Rohaizad, Carmen C. Mayorga-Martinez, Michaela Fojtu, Naziah M. Latiff, Martin Pumera | | Chemical Society Reviews. 2021; 50(1): 619 | | [Pubmed] | [DOI] | | | 96 |
Aptamers: an emerging navigation tool of therapeutic agents for targeted cancer therapy |
|
| Chang Yang, Yu Jiang, Sai Heng Hao, Xing Yi Yan, De Fei Hong, Hua Naranmandura | | Journal of Materials Chemistry B. 2021; | | [Pubmed] | [DOI] | | | 97 |
Irisin ameliorates doxorubicin-induced cardiac perivascular fibrosis through inhibiting endothelial-to-mesenchymal transition by regulating ROS accumulation and autophagy disorder in endothelial cells |
|
| Jian-an Pan, Hui Zhang, Hao Lin, Lin Gao, Hui-li Zhang, Jun-feng Zhang, Chang-qian Wang, Jun Gu | | Redox Biology. 2021; 46: 102120 | | [Pubmed] | [DOI] | | | 98 |
Enhanced therapeutic index of liposomal doxorubicin Myocet locally delivered by fibrin gels in immunodeficient mice bearing human neuroblastoma |
|
| Maurizio Viale, Vittorio Bertone, Irena Maric, Michele Cilli, Laura Emionite, Vittorio Bocchini, Mirco Ponzoni, Vincenzo Fontana, Fabrizio De Luca, Mattia Rocco | | Pharmacological Research. 2021; 163: 105294 | | [Pubmed] | [DOI] | | | 99 |
Evidences for the mechanism of Shenmai injection antagonizing doxorubicin-induced cardiotoxicity |
|
| You-Ping Wu, Sheng Zhang, Yan-Fei Xin, Li-Qiang Gu, Xiao-Zhen Xu, Cheng-Da Zhang, Zhen-Qiang You | | Phytomedicine. 2021; 88: 153597 | | [Pubmed] | [DOI] | | | 100 |
Treatment outcome of doxorubicin versus idarubicin in adult acute myeloid leukemia |
|
| Hemat Afifi Sherif, Ahmed Magdy, Heba Anees Elshesheni, Sherein Mahmoud Ramadan, Reham A. Rashed | | Leukemia Research Reports. 2021; 16: 100272 | | [Pubmed] | [DOI] | | | 101 |
Tumor targeting antibody-conjugated nanocarrier with pH/thermo dual-responsive macromolecular film layer for enhanced cancer chemotherapy |
|
| Jiafeng Zhuang, Lina Zhou, Wen Tang, Tonghao Ma, Hui Li, Xiaoli Wang, Chao Chen, Ping Wang | | Materials Science and Engineering: C. 2021; 118: 111361 | | [Pubmed] | [DOI] | | | 102 |
Doxorubicin nanoformulations on therapy against cancer: An overview from the last 10?years |
|
| Natália A. D'Angelo, Mariana A. Noronha, Mayra C.C. Câmara, Isabelle S. Kurnik, Chuying Feng, Victor H.S. Araujo, João H.P.M. Santos, Valker Feitosa, João V.D. Molino, Carlota O. Rangel-Yagui, Marlus Chorilli, Emmanuel Ho, André M. Lopes | | Materials Science and Engineering: C. 2021; : 112623 | | [Pubmed] | [DOI] | | | 103 |
Cellulose acetate encapsulated upconversion nanoparticles – A novel theranostic platform |
|
| Seda Demirel Topel, Sevgi Balcioglu, Burhan Ates, Meltem Asilturk, Önder Topel, Marica B. Ericson | | Materials Today Communications. 2021; 26: 101829 | | [Pubmed] | [DOI] | | | 104 |
Nano-immunotherapy: Unique mechanisms of nanomaterials in synergizing cancer immunotherapy |
|
| Quan Liu, Yanhong Duo, Jianye Fu, Meng Qiu, Zhe Sun, Dickson Adah, Jianlong Kang, Zhongjian Xie, Taojian Fan, Shiyun Bao, Han Zhang, Li-Ping Liu, Yihai Cao | | Nano Today. 2021; 36: 101023 | | [Pubmed] | [DOI] | | | 105 |
Synergetic effect of adsorption-photocatalysis by GO-CeO2nanocomposites for photodegradation of doxorubicin |
|
| M. Ali Abbasi, Khaled M. Amin, Mubarak Ali, Zulqurnain Ali, Muhammad Atif, Wolfgang Ensinger, Waqas Khalid | | Journal of Environmental Chemical Engineering. 2021; : 107078 | | [Pubmed] | [DOI] | | | 106 |
Liposomal doxorubicin as targeted delivery platform: Current trends in surface functionalization |
|
| Vivek Makwana, Jasmine Karanjia, Thomas Haselhorst, Shailendra Anoopkumar-Dukie, Santosh Rudrawar | | International Journal of Pharmaceutics. 2021; 593: 120117 | | [Pubmed] | [DOI] | | | 107 |
Construction and antitumor properties of a targeted nano-drug carrier system responsive to the tumor microenvironment |
|
| Wenzhao Han, Junfeng Ke, Feng Guo, Fanwei Meng, Hui Li, Liping Wang | | International Journal of Pharmaceutics. 2021; 608: 121066 | | [Pubmed] | [DOI] | | | 108 |
Preparation and characterization of PEGylated liposomal Doxorubicin targeted with leptin-derived peptide and evaluation of their anti-tumor effects, in vitro and in vivo in mice bearing C26 colon carcinoma |
|
| Naghmeh Shahraki, Amin Mehrabian, Shahrazad Amiri-Darban, Seyedeh Alia Moosavian, Mahmoud Reza Jaafari | | Colloids and Surfaces B: Biointerfaces. 2021; 200: 111589 | | [Pubmed] | [DOI] | | | 109 |
Identification and validation of a prognostic signature and combination drug therapy for immunotherapy of head and neck squamous cell carcinoma |
|
| Weijie Qiang, Yifei Dai, Xiaoyan Xing, Xiaobo Sun | | Computational and Structural Biotechnology Journal. 2021; 19: 1263 | | [Pubmed] | [DOI] | | | 110 |
Sensitive analysis of doxorubicin and curcumin by micellar electromagnetic chromatography with a double wavelength excitation source |
|
| Xiao Yu, Wanxiang Yu, Xiufen Han, Zuanguang Chen, Shumei Wang, Haiyun Zhai | | Analytical and Bioanalytical Chemistry. 2021; 413(2): 469 | | [Pubmed] | [DOI] | | | 111 |
Folic acid-appended galactoxyloglucan-capped iron oxide nanoparticles as a biocompatible nanotheranostic agent for tumor-targeted delivery of doxorubicin |
|
| B.S. Unnikrishnan, Anitha Sen, G.U. Preethi, Manu M. Joseph, S. Maya, R. Shiji, K.S. Anusree, T.T. Sreelekha | | International Journal of Biological Macromolecules. 2021; 168: 130 | | [Pubmed] | [DOI] | | | 112 |
Doxorubicin delivery by magnetic nanotheranostics enhances the cell death in chemoresistant colorectal cancer-derived cells |
|
| María Julia Martín, Pamela Azcona, Verónica Lassalle, Claudia Gentili | | European Journal of Pharmaceutical Sciences. 2021; 158: 105681 | | [Pubmed] | [DOI] | | | 113 |
Folic acid-doxorubicin polymeric nanocapsules: A promising formulation for the treatment of triple-negative breast cancer |
|
| Rodrigo Cé, Gabriela Klein Couto, Barbara Zoche Pacheco, Danieli Rosane Dallemole, Júlia Damé Paschoal, Bruna Silveira Pacheco, Silvia Stanisçuaski Guterres, Fabiana Seixas, Tiago Collares, Adriana Raffin Pohlmann | | European Journal of Pharmaceutical Sciences. 2021; 165: 105943 | | [Pubmed] | [DOI] | | | 114 |
Doxorubicin suppresses chondrocyte differentiation by stimulating ROS production |
|
| Cheng Wu, Jiayi Luo, Yuanxin Liu, Jiannan Fan, Xianwen Shang, Riguang Liu, Chuan Ye, Jihong Yang, Hong Cao | | European Journal of Pharmaceutical Sciences. 2021; 167: 106013 | | [Pubmed] | [DOI] | | | 115 |
Effective drug delivery system based on hydrophobin and halloysite clay nanotubes for sustained release of doxorubicin |
|
| Bo Wang, Zhiqiang Han, Bo Song, Long Yu, Zhongqiang Ma, Haijin Xu, Mingqiang Qiao | | Colloids and Surfaces A: Physicochemical and Engineering Aspects. 2021; 628: 127351 | | [Pubmed] | [DOI] | | | 116 |
Incidence and risk factors for oral mucositis in pediatric patients receiving chemotherapy |
|
| Marina Curra, Amanda F. Gabriel, Maria Beatriz C. Ferreira, Marco Antonio T. Martins, André T. Brunetto, Lauro J. Gregianin, Manoela Domingues Martins | | Supportive Care in Cancer. 2021; 29(11): 6243 | | [Pubmed] | [DOI] | | | 117 |
The role of miRNAs in colorectal cancer progression and chemoradiotherapy |
|
| Ning Zhang, Xianyu Hu, Yinan Du, Juan Du | | Biomedicine & Pharmacotherapy. 2021; 134: 111099 | | [Pubmed] | [DOI] | | | 118 |
The nephroprotective effects and mechanisms of rehmapicrogenin include ROS inhibition via an oestrogen-like pathway both in vivo and in vitro |
|
| Mengmeng Wang, Yingying Ke, Yage Li, Zengfu Shan, Wangyang Mi, Yangang Cao, Weisheng Feng, Xiaoke Zheng | | Biomedicine & Pharmacotherapy. 2021; 138: 111305 | | [Pubmed] | [DOI] | | | 119 |
DNA damaging agents and DNA repair: From carcinogenesis to cancer therapy |
|
| Larissa Costa de Almeida, Felipe Antunes Calil, João Agostinho Machado-Neto, Leticia Veras Costa-Lotufo | | Cancer Genetics. 2021; 252-253: 6 | | [Pubmed] | [DOI] | | | 120 |
Intracellular RNA and nuclear DNA-dual-targeted tumor therapy via upconversion nanoplatforms with UCL/MR dual-mode bioimaging |
|
| Bo Teng, Binbin Ding, Shuai Shao, Zhanfeng Wang, Weifang Tong, Sanchun Wang, Ziyong Cheng, Jun Lin, Ping'an Ma | | Chemical Engineering Journal. 2021; 405: 126606 | | [Pubmed] | [DOI] | | | 121 |
A bioimaging system combining human cultured reporter cells and planar chromatography to identify novel bioactive molecules |
|
| Ines Klingelhöfer, Long Pham Ngoc, Bart van der Burg, Gertrud E. Morlock | | Analytica Chimica Acta. 2021; 1183: 338956 | | [Pubmed] | [DOI] | | | 122 |
Sustained and controlled delivery of doxorubicin from an in-situ setting biphasic hydroxyapatite carrier for local treatment of a highly proliferative human osteosarcoma |
|
| Yang Liu, Deepak Bushan Raina, Sujeesh Sebastian, Harshitha Nagesh, Hanna Isaksson, Jacob Engellau, Lars Lidgren, Magnus Tägil | | Acta Biomaterialia. 2021; 131: 555 | | [Pubmed] | [DOI] | | | 123 |
Optical properties of natural small molecules and their applications in imaging and nanomedicine |
|
| Hao Yuan, Ao Jiang, Hongbao Fang, Yuncong Chen, Zijian Guo | | Advanced Drug Delivery Reviews. 2021; : 113917 | | [Pubmed] | [DOI] | | | 124 |
Application of new multicomponent nanosystems for overcoming doxorubicin resistance in breast cancer therapy |
|
| Nataliya Kutsevol, Yuliia Kuziv, Tetiana Bezugla, Pavlo Virych, Andrii Marynin, Tetiana Borikun, Natalia Lukianova, Petro Virych, Vasyl Chekhun | | Applied Nanoscience. 2021; | | [Pubmed] | [DOI] | | | 125 |
Cyclodextrin-based delivery systems for in vivo-tested anticancer therapies |
|
| Ana Cláudia Santos, Diana Costa, Laura Ferreira, Catarina Guerra, Miguel Pereira-Silva, Irina Pereira, Diana Peixoto, Nuno R. Ferreira, Francisco Veiga | | Drug Delivery and Translational Research. 2021; 11(1): 49 | | [Pubmed] | [DOI] | | | 126 |
Matrix Metalloproteinase-9-Responsive Surface Charge-Reversible Nanocarrier to Enhance Endocytosis as Efficient Targeted Delivery System for Cancer Diagnosis and Therapy |
|
| Qiu-Ju Han, Xiao-Tong Lan, Ying Wen, Chuan-Zeng Zhang, Michael Cleary, Yasra Sayyed, Guangdong Huang, Xiaoling Tuo, Long Yi, Zhen Xi, Lu-Yuan Li, Qiang-Zhe Zhang | | Advanced Healthcare Materials. 2021; 10(9): 2002143 | | [Pubmed] | [DOI] | | | 127 |
Multi-Functional Liposome: A Powerful Theranostic Nano-Platform Enhancing Photodynamic Therapy |
|
| Xiamin Cheng, Jing Gao, Yang Ding, Yao Lu, Qiancheng Wei, Dezhi Cui, Jiali Fan, Xiaoman Li, Ershu Zhu, Yongna Lu, Qiong Wu, Lin Li, Wei Huang | | Advanced Science. 2021; 8(16): 2100876 | | [Pubmed] | [DOI] | | | 128 |
Perspectives and controversies regarding the use of natural products for the treatment of lung cancer |
|
| Tingting Wen, Lei Song, Shucheng Hua | | Cancer Medicine. 2021; 10(7): 2396 | | [Pubmed] | [DOI] | | | 129 |
The Use of Phospholipids to Make Pharmaceutical Form Line Extensions |
|
| Peter Hoogevest, Harry Tiemessen, Josbert M. Metselaar, Simon Drescher, Alfred Fahr | | European Journal of Lipid Science and Technology. 2021; 123(4): 2000297 | | [Pubmed] | [DOI] | | | 130 |
Thymoquinone attenuates doxorubicin-cardiotoxicity in rats |
|
| Derya Karabulut, Emel Ozturk, Emin Kaymak, Ali Tugrul Akin, Birkan Yakan | | Journal of Biochemical and Molecular Toxicology. 2021; 35(1) | | [Pubmed] | [DOI] | | | 131 |
Thymoquinone has a neuroprotective effect against inflammation, oxidative stress, and endoplasmic reticulum stress in the brain cortex, medulla, and hippocampus due to doxorubicin |
|
| Emin Kaymak, Ali Tugrul Akin, Emel Öztürk, Derya Karabulut, Nurhan Kuloglu, Birkan Yakan | | Journal of Biochemical and Molecular Toxicology. 2021; 35(11) | | [Pubmed] | [DOI] | | | 132 |
A quantitative systems pharmacology approach to predict the safe-equivalent dose of doxorubicin in patients with cardiovascular comorbidity |
|
| Lan Sang, Yi Yuan, Ying Zhou, Zhengying Zhou, Muhan Jiang, Xiaoquan Liu, Kun Hao, Hua He | | CPT: Pharmacometrics & Systems Pharmacology. 2021; | | [Pubmed] | [DOI] | | | 133 |
Ribosomal protein
L5
mediated inhibition of
c-Myc
is critically involved in sanggenon G induced apoptosis in non-small lung cancer cells
|
|
| Ji Eon Park, Ji Hoon Jung, Hyo-Jung Lee, Deok Yong Sim, Eunji Im, Woon Yi Park, Bum Sang Shim, Seong-Gyu Ko, Sung-Hoon Kim | | Phytotherapy Research. 2021; 35(2): 1080 | | [Pubmed] | [DOI] | | | 134 |
Advances in engineering local drug delivery systems for cancer immunotherapy |
|
| Peter Abdou, Zejun Wang, Qian Chen, Amanda Chan, Daojia R. Zhou, Vivienne Gunadhi, Zhen Gu | | WIREs Nanomedicine and Nanobiotechnology. 2020; 12(5) | | [Pubmed] | [DOI] | | | 135 |
2D Germanane Derivative as a Vector for Overcoming Doxorubicin Resistance in Cancer Cells |
|
| Michaela Fojtu, Jan Balvan, Martina Raudenská, Tomáš Vicar, Jirí Šturala, Zdenek Sofer, Jan Luxa, Jan Plutnar, Michal Masarík, Martin Pumera | | Applied Materials Today. 2020; 20: 100697 | | [Pubmed] | [DOI] | | | 136 |
Protein phosphatase 1 in tumorigenesis: is it worth a closer look? |
|
| Juliana Felgueiras, Carmen Jerónimo, Margarida Fardilha | | Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2020; 1874(2): 188433 | | [Pubmed] | [DOI] | | | 137 |
Preparation and in vitro/in vivo evaluation of doxorubicin-loaded poly[lactic-co-glycol acid] microspheres using electrospray method for sustained drug delivery and potential intratumoral injection |
|
| Ming-Yi Hsu, Yu-Ting Huang, Chun-Jui Weng, Chien-Ming Chen, Yong-Fong Su, Sung-Yu Chu, Jeng-Hwei Tseng, Ren-Chin Wu, Shih-Jung Liu | | Colloids and Surfaces B: Biointerfaces. 2020; 190: 110937 | | [Pubmed] | [DOI] | | | 138 |
Hypoxia-sensitive micellar nanoparticles for co-delivery of siRNA and chemotherapeutics to overcome multi-drug resistance in tumor cells |
|
| Ujjwal Joshi, Nina Filipczak, Muhammad Muzamil Khan, Sara Aly Attia, Vladimir Torchilin | | International Journal of Pharmaceutics. 2020; 590: 119915 | | [Pubmed] | [DOI] | | | 139 |
Alginate microbeads with internal microvoids for the sustained release of drugs |
|
| Stefania Boi, Nadia Rouatbi, Elena Dellacasa, Donatella Di Lisa, Paolo Bianchini, Orietta Monticelli, Laura Pastorino | | International Journal of Biological Macromolecules. 2020; 156: 454 | | [Pubmed] | [DOI] | | | 140 |
Doxorubicin-loaded composite nanogels for cancer treatment |
|
| Marzieh Mohammadi, Leila Arabi, Mona Alibolandi | | Journal of Controlled Release. 2020; 328: 171 | | [Pubmed] | [DOI] | | | 141 |
In vitro irradiation of doxorubicin with 18F-FDG Cerenkov radiation and its potential application as a theragnostic system. |
|
| Hilda Angeline Quintos-Meneses, Liliana Aranda-Lara, Enrique Morales-Ávila, Eugenio Torres-García, Miguel Ángel Camacho-López, Mariana Sánchez-Holguín, Myrna A. Luna-Gutiérrez, Ninfa Ramírez-Durán, Keila Isaac-Olivé | | Journal of Photochemistry and Photobiology B: Biology. 2020; 210: 111961 | | [Pubmed] | [DOI] | | | 142 |
Arctigenin, a novel TMEM16A inhibitor for lung adenocarcinoma therapy |
|
| Shuai Guo, Yafei Chen, Sai Shi, Xuzhao Wang, Hailin Zhang, Yong Zhan, Hailong An | | Pharmacological Research. 2020; 155: 104721 | | [Pubmed] | [DOI] | | | 143 |
New molecular and biochemical insights of doxorubicin-induced hepatotoxicity |
|
| Pureti Lakshmi Prasanna, Kaviyarasi Renu, Abilash Valsala Gopalakrishnan | | Life Sciences. 2020; 250: 117599 | | [Pubmed] | [DOI] | | | 144 |
Graphene oxide as a potential drug carrier – Chemical carrier activation, drug attachment and its enzymatic controlled release |
|
| Anna Trusek, Edward Kijak, Ludomira Granicka | | Materials Science and Engineering: C. 2020; 116: 111240 | | [Pubmed] | [DOI] | | | 145 |
Extracellular vesicles as natural therapeutic agents and innate drug delivery systems for cancer treatment: Recent advances, current obstacles, and challenges for clinical translation |
|
| Marco Pirisinu, Tin Chanh Pham, Daniel Xin Zhang, Tran Nguyen Hong, Lap Thi Nguyen, Minh TN Le | | Seminars in Cancer Biology. 2020; | | [Pubmed] | [DOI] | | | 146 |
Reversing P-Glycoprotein-Associated Multidrug Resistance of Breast Cancer by Targeted Acid-Cleavable Polysaccharide Nanoparticles with Lapatinib Sensitization |
|
| Junhui Sui, Mengmeng He, Yuedi Yang, Mengcheng Ma, Zhihao Guo, Mingda Zhao, Jie Liang, Yong Sun, Yujiang Fan, Xingdong Zhang | | ACS Applied Materials & Interfaces. 2020; 12(46): 51198 | | [Pubmed] | [DOI] | | | 147 |
Facile Fabrication Route of Janus Gold-Mesoporous Silica Nanocarriers with Dual-Drug Delivery for Tumor Therapy |
|
| Yang Xing, Ying Zhou, Yan Zhang, Caihong Zhang, Xu Deng, Chuan Dong, Shaomin Shuang | | ACS Biomaterials Science & Engineering. 2020; 6(3): 1573 | | [Pubmed] | [DOI] | | | 148 |
Effect of TAT-DOX-PEG irradiated gold nanoparticles conjugates on human osteosarcoma cells |
|
| Raoul V. Lupusoru, Daniela A. Pricop, Cristina M. Uritu, Adina Arvinte, Adina Coroaba, Irina Esanu, Mirela F. Zaltariov, Mihaela Silion, Cipriana Stefanescu, Mariana Pinteala | | Scientific Reports. 2020; 10(1) | | [Pubmed] | [DOI] | | | 149 |
Co-delivery of Doxorubicin and Curcumin with Polypeptide Nanocarrier for Synergistic Lymphoma Therapy |
|
| Wei Guo, Yuanyuan Song, Wantong Song, Yingmin Liu, Zhihe Liu, Dawei Zhang, Zhaohui Tang, Ou Bai | | Scientific Reports. 2020; 10(1) | | [Pubmed] | [DOI] | | | 150 |
The implications of mitochondria in doxorubicin treatment of cancer in the context of traditional and modern medicine |
|
| Leonardo da Cunha Menezes Souza, Meng Chen, Yuji Ikeno, Daisy Maria Fávero Salvadori, Yidong Bai | | Traditional Medicine and Modern Medicine. 2020; 03(04): 239 | | [Pubmed] | [DOI] | | | 151 |
Dexrazoxane Protects Cardiomyocyte from Doxorubicin-Induced Apoptosis by Modulating miR-17-5p |
|
| Xiaoxue Yu, Yang Ruan, Tao Shen, Quan Qiu, Mingjing Yan, Shenghui Sun, Lin Dou, Xiuqing Huang, Que Wang, Xiyue Zhang, Yong Man, Weiqing Tang, Zening Jin, Jian Li | | BioMed Research International. 2020; 2020: 1 | | [Pubmed] | [DOI] | | | 152 |
Protective Effect of miR-204 on Doxorubicin-Induced Cardiomyocyte Injury via HMGB1 |
|
| Youyou Du, Guanghui Liu, Luosha Zhao, Rui Yao, Ding Sheng Jiang | | Oxidative Medicine and Cellular Longevity. 2020; 2020: 1 | | [Pubmed] | [DOI] | | | 153 |
Genomic instability and cancer: lessons from
Drosophila
|
|
| Stephan U. Gerlach, Héctor Herranz | | Open Biology. 2020; 10(6): 200060 | | [Pubmed] | [DOI] | | | 154 |
Doxorubicin delivery by polymer nanocarrier based on N-methylglucamine resorcinarene |
|
| Tatiana Yu. Sergeeva, Rezeda K. Mukhitova, Leysan R. Bakhtiozina, Irek R. Nizameev, Marsil K. Kadirov, Anastasia S. Sapunova, Alexandra D. Voloshina, Albina Y. Ziganshina, Igor S. Antipin | | Supramolecular Chemistry. 2020; 32(2): 150 | | [Pubmed] | [DOI] | | | 155 |
Development of stimuli-responsive intelligent polymer micelles for the delivery of doxorubicin |
|
| Fan Yang, Jiangkang Xu, Manfei Fu, Jianbo Ji, Liqun Chi, Guangxi Zhai | | Journal of Drug Targeting. 2020; 28(10): 993 | | [Pubmed] | [DOI] | | | 156 |
Reticulocalbin-1 knockdown increases the sensitivity of cells to Adriamycin in nasopharyngeal carcinoma and promotes endoplasmic reticulum stress-induced cell apoptosis |
|
| Ze-Hao Huang, Jun Qiao, Yi-Yang Feng, Meng-Ting Qiu, Ting Cheng, Jia Wang, Chao-Feng Zheng, Zhi-Qin Lv, Cai-Hong Wang | | Cell Cycle. 2020; 19(13): 1576 | | [Pubmed] | [DOI] | | | 157 |
Differential changes in the pharmacokinetics of doxorubicin in diethylnitrosamine-induced hepatocarcinoma model rats |
|
| Jie Pan, Yuan Lu, Shuai Zhang, Yueting Li, Jia Sun, Hua Chunhua Liu, Zipeng Gong, Jing Huang, Chuang Cao, Yonglin Wang, Yongjun Li, Ting Liu | | Xenobiotica. 2020; 50(10): 1251 | | [Pubmed] | [DOI] | | | 158 |
Pluronic P123 modified nano micelles loaded with doxorubicin enhanced tumor-suppressing effect on drug-resistant breast cancer cells |
|
| Xiaoyu Zhang, Weibin Chen, Jie Bai, Lijun Jin, Xiaoning Kang, Hui Zhang, Zunyi Wang | | Aging. 2020; 12(9): 8289 | | [Pubmed] | [DOI] | | | 159 |
Modification of graphene oxide by angiopep-2 enhances anti-glioma efficiency of the nanoscaled delivery system for doxorubicin |
|
| Yue Zhao, Hang Yin, Xiaoyu Zhang | | Aging. 2020; 12(11): 10506 | | [Pubmed] | [DOI] | | | 160 |
Preparation, characterization, and in vitro evaluation of amphiphilic peptide P12 and P12-DOX nanomicelles as antitumor drug carriers |
|
| Ping Song, Wuchen Du, Wanzhen Li, Longbao Zhu, Weiwei Zhang, Xinxing Gao, Yugui Tao, Fei Ge | | Nanomaterials and Nanotechnology. 2020; 10: 1847980420 | | [Pubmed] | [DOI] | | | 161 |
Anthracycline-related cardiotoxicity in older patients with acute myeloid leukemia: a Young SIOG review paper |
|
| Nina Rosa Neuendorff, Kah Poh Loh, Alice S. Mims, Konstantinos Christofyllakis, Wee-Kheng Soo, Bediha Bölükbasi, Carlos Oñoro-Algar, William G. Hundley, Heidi D. Klepin | | Blood Advances. 2020; 4(4): 762 | | [Pubmed] | [DOI] | | | 162 |
Protective role of black seed oil in doxorubicin-induced cardiac toxicity in children with acute lymphoblastic leukemia |
|
| Adel A Hagag, Ibrahim M Badraia, Walid A El-Shehaby, Maaly M Mabrouk | | Journal of Oncology Pharmacy Practice. 2020; 26(6): 1397 | | [Pubmed] | [DOI] | | | 163 |
Galectin-3 inhibition attenuates doxorubicin-induced cardiac dysfunction by upregulating the expression of peroxiredoxin-4 |
|
| Yunpeng Tian, Wei Lv, Chengzhi Lu, Yiyao Jiang, Xue Yang, Minghao Song | | Canadian Journal of Physiology and Pharmacology. 2020; 98(10): 700 | | [Pubmed] | [DOI] | | | 164 |
Tumor in 3D: In Vitro Complex Cellular Models to Improve Nanodrugs Cancer Therapy |
|
| Soraia Fernandes, Marco Cassani, Stefania Pagliari, Petr Filipensky, Francesca Cavalieri, Giancarlo Forte | | Current Medicinal Chemistry. 2020; 27(42): 7234 | | [Pubmed] | [DOI] | | | 165 |
Key Signaling Pathways Engaged in Cancer Management: Current Update |
|
| Sanjiv Singh, Rahul Shukla | | Current Cancer Therapy Reviews. 2020; 16(1): 36 | | [Pubmed] | [DOI] | | | 166 |
Drug Delivery Approaches for Doxorubicin in the Management of Cancers |
|
| Manish Vyas, Daniel A. Simbo, Mohd. Mursalin, Vijay Mishra, Roqia Bashary, Gopal L. Khatik | | Current Cancer Therapy Reviews. 2020; 16(4): 320 | | [Pubmed] | [DOI] | | | 167 |
Ditelluride-Bridged PEG-PCL Copolymer as Folic Acid-Targeted and Redox-Responsive Nanoparticles for Enhanced Cancer Therapy |
|
| Zekun Pang, Jiayan Zhou, Chunyang Sun | | Frontiers in Chemistry. 2020; 8 | | [Pubmed] | [DOI] | | | 168 |
Human Pluripotent Stem Cell-Derived Cardiomyocytes for Assessment of Anticancer Drug-Induced Cardiotoxicity |
|
| Verena Schwach, Rolf H. Slaats, Robert Passier | | Frontiers in Cardiovascular Medicine. 2020; 7 | | [Pubmed] | [DOI] | | | 169 |
Krebs Cycle Intermediate-Modified Carbonate Apatite Nanoparticles Drastically Reduce Mouse Tumor Burden and Toxicity by Restricting Broad Tissue Distribution of Anticancer Drugs |
|
| Sultana Mehbuba Hossain, Syafiq Asnawi Zainal Abidin, Ezharul Hoque Chowdhury | | Cancers. 2020; 12(1): 161 | | [Pubmed] | [DOI] | | | 170 |
Signal transducer and activator of transcription 6 as a target in colon cancer therapy (Review) |
|
| Yael Delgado-Ramirez, Vaneesa Colly, Giovanni Villanueva Gonzalez, Sonia Leon-Cabrera | | Oncology Letters. 2020; 20(1): 455 | | [Pubmed] | [DOI] | | | 171 |
Assessing Advantages and Drawbacks of Rapidly Generated Ultra-Large 3D Breast Cancer Spheroids: Studies with Chemotherapeutics and Nanoparticles |
|
| Austin R. Holub, Anderson Huo, Kavil Patel, Vishal Thakore, Pranav Chhibber, Folarin Erogbogbo | | International Journal of Molecular Sciences. 2020; 21(12): 4413 | | [Pubmed] | [DOI] | | | 172 |
Liposomes for Intra-Articular Analgesic Drug Delivery in Orthopedics: State-of-Art and Future Perspectives. Insights from a Systematic Mini-Review of the Literature |
|
| Lucio Cipollaro, Paolo Trucillo, Nicola Luigi Bragazzi, Giovanna Della Porta, Ernesto Reverchon, Nicola Maffulli | | Medicina. 2020; 56(9): 423 | | [Pubmed] | [DOI] | | | 173 |
Liquid Chromatography–Tandem Mass Spectrometry for the Simultaneous Determination of Doxorubicin and its Metabolites Doxorubicinol, Doxorubicinone, Doxorubicinolone, and 7-Deoxydoxorubicinone in Mouse Plasma |
|
| Won-Gu Choi, Dong Kyun Kim, Yongho Shin, Ria Park, Yong-Yeon Cho, Joo Young Lee, Han Chang Kang, Hye Suk Lee | | Molecules. 2020; 25(5): 1254 | | [Pubmed] | [DOI] | | | 174 |
Doxorubicin Loaded Poloxamer Thermosensitive Hydrogels: Chemical, Pharmacological and Biological Evaluation |
|
| Chih Kit Chung, Jomarien García-Couce, Yaima Campos, Dana Kralisch, Katja Bierau, Alan Chan, Ferry Ossendorp, Luis Javier Cruz | | Molecules. 2020; 25(9): 2219 | | [Pubmed] | [DOI] | | | 175 |
Antitumor Features of Vegetal Protein-Based Nanotherapeutics |
|
| Silvia Voci, Agnese Gagliardi, Massimo Fresta, Donato Cosco | | Pharmaceutics. 2020; 12(1): 65 | | [Pubmed] | [DOI] | | | 176 |
The Basement Membrane in a 3D Breast Acini Model Modulates Delivery and Anti-Proliferative Effects of Liposomal Anthracyclines |
|
| Tabea Wiedenhoeft, Tobias Braun, Ronald Springer, Michael Teske, Erik Noetzel, Rudolf Merkel, Agnes Csiszár | | Pharmaceuticals. 2020; 13(9): 256 | | [Pubmed] | [DOI] | | | 177 |
Titanium Dioxide Nanoparticles: Prospects and Applications in Medicine |
|
| Daniel Ziental, Beata Czarczynska-Goslinska, Dariusz T. Mlynarczyk, Arleta Glowacka-Sobotta, Beata Stanisz, Tomasz Goslinski, Lukasz Sobotta | | Nanomaterials. 2020; 10(2): 387 | | [Pubmed] | [DOI] | | | 178 |
Toxicity of Carbon Nanomaterials and Their Potential Application as Drug Delivery Systems: In Vitro Studies in Caco-2 and MCF-7 Cell Lines |
|
| Rosa Garriga, Tania Herrero-Continente, Miguel Palos, Vicente L. Cebolla, Jesús Osada, Edgar Muñoz, María Jesús Rodríguez-Yoldi | | Nanomaterials. 2020; 10(8): 1617 | | [Pubmed] | [DOI] | | | 179 |
Design and Synthesis of Multi-Functional Superparamagnetic Core-Gold Shell Nanoparticles Coated with Chitosan and Folate for Targeted Antitumor Therapy |
|
| Sharafaldin Al-Musawi, Salim Albukhaty, Hassan Al-Karagoly, Faizah Almalki | | Nanomaterials. 2020; 11(1): 32 | | [Pubmed] | [DOI] | | | 180 |
Copolymacrolactones Grafted with l-Glutamic Acid: Synthesis, Structure, and Nanocarrier Properties |
|
| Ernesto Tinajero-Díaz, Antxon Martínez de Ilarduya, Sebastián Muñoz-Guerra | | Polymers. 2020; 12(4): 995 | | [Pubmed] | [DOI] | | | 181 |
Doxorubicin-Conjugated Iron Oxide Nanoparticles Synthesized by Laser Pyrolysis: In Vitro Study on Human Breast Cancer Cells |
|
| Iulia Ioana Lungu, Simona Nistorescu, Madalina Andreea Badea, Andreea-Mihaela Petre, Ana-Maria Udrea, Ana-Maria Banici, Claudiu Fleaca, Ecaterina Andronescu, Anca Dinischiotu, Florian Dumitrache, Angela Staicu, Mihaela Bala? | | Polymers. 2020; 12(12): 2799 | | [Pubmed] | [DOI] | | | 182 |
Extracts of Bridelia ovata and Croton oblongifolius induce apoptosis in human MDA-MB-231 breast cancer cells via oxidative stress and mitochondrial pathways |
|
| Juthathip Poofery, Bungorn Sripanidkulchai, Ratana Banjerdpongchai | | International Journal of Oncology. 2020; | | [Pubmed] | [DOI] | | | 183 |
Low-intensity ultrasound enhances the antitumor effects of doxorubicin on hepatocellular carcinoma cells through the ROS-miR-21-PTEN axis |
|
| Chunhua Xia, Huabei Zeng, Yanfen Zheng | | Molecular Medicine Reports. 2020; | | [Pubmed] | [DOI] | | | 184 |
MicroRNA-33a-5p overexpression sensitizes triple-negative breast cancer to doxorubicin by inhibiting eIF5A2 and epithelial-mesenchymal transition |
|
| Xiaoqing Guan, Shucheng Gu, Mu Yuan, Xiangxin Zheng, Ji Wu | | Oncology Letters. 2019; | | [Pubmed] | [DOI] | | | 185 |
Multiplex Three-Dimensional Mapping of Macromolecular Drug Distribution in the Tumor Microenvironment |
|
| Steve Seung-Young Lee, Vytautas P. Bindokas, Stephen J. Kron | | Molecular Cancer Therapeutics. 2019; 18(1): 213 | | [Pubmed] | [DOI] | | | 186 |
Cardioprotective Effect of Phase 3 Clinical Anticancer Agent, RRx-001, in Doxorubicin-Induced Acute Cardiotoxicity in Mice |
|
| Bryan Oronsky, Eilleen S. Y. Ao-Ieong, Ozlem Yalcin, Corey A. Carter, Pedro Cabrales | | Molecular Pharmaceutics. 2019; 16(7): 2929 | | [Pubmed] | [DOI] | | | 187 |
Active Targeting of Cancer Cells by Nanobody Decorated Polypeptide Micelle with Bio-orthogonally Conjugated Drug |
|
| Simone A. Costa, Davoud Mozhdehi, Michael J. Dzuricky, Farren J. Isaacs, Eric M. Brustad, Ashutosh Chilkoti | | Nano Letters. 2019; 19(1): 247 | | [Pubmed] | [DOI] | | | 188 |
Phase-Change Material Packaged within Hollow Copper Sulfide Nanoparticles Carrying Doxorubicin and Chlorin e6 for Fluorescence-Guided Trimodal Therapy of Cancer |
|
| Qian Li, Lihong Sun, Mengmeng Hou, Qiubing Chen, Ruihao Yang, Lei Zhang, Zhigang Xu, Yuejun Kang, Peng Xue | | ACS Applied Materials & Interfaces. 2019; 11(1): 417 | | [Pubmed] | [DOI] | | | 189 |
pH-Responsive diblock copolymers made of ?-pentadecalactone and ionically charged a-amino acids |
|
| Ernesto Tinajero-Díaz, Antxon Martínez de Ilarduya, Sebastián Muñoz-Guerra | | European Polymer Journal. 2019; 120: 109244 | | [Pubmed] | [DOI] | | | 190 |
Cerium oxide nanoparticles: In pursuit of liver protection against doxorubicin-induced injury in rats |
|
| Heba G. Ibrahim, Noha Attia, Fatma El Zahraa A. Hashem, Moushira A.R. El Heneidy | | Biomedicine & Pharmacotherapy. 2018; 103: 773 | | [Pubmed] | [DOI] | | | 191 |
Photoresponsive Micelle-Incorporated Doxorubicin for Chemo-Photodynamic Therapy to Achieve Synergistic Antitumor Effects |
|
| Da Hye Kim, Hee Sook Hwang, Kun Na | | Biomacromolecules. 2018; 19(8): 3301 | | [Pubmed] | [DOI] | | | 192 |
Topoisomerases as anticancer targets |
|
| Justine L. Delgado, Chao-Ming Hsieh, Nei-Li Chan, Hiroshi Hiasa | | Biochemical Journal. 2018; 475(2): 373 | | [Pubmed] | [DOI] | | | 193 |
Targeted delivery of cisplatin to tumor xenografts via the nanoparticle component of nano-diamino-tetrac |
|
| Thangirala Sudha, Dhruba J Bharali, Murat Yalcin, Noureldien HE Darwish, Melis Debreli Coskun, Kelly A Keating, Hung-Yun Lin, Paul J Davis, Shaker A Mousa | | Nanomedicine. 2017; 12(3): 195 | | [Pubmed] | [DOI] | | | 194 |
Quercetin reverses the doxorubicin resistance of prostate cancer cells by downregulating the expression of c-met |
|
| Yan Shu, Bo Xie, Zhen Liang, Jing Chen | | Oncology Letters. 2017; | | [Pubmed] | [DOI] | | | 195 |
Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics |
|
| Rosie Elizabeth Ann Gutteridge, Mary Ann Ndiaye, Xiaoqi Liu, Nihal Ahmad | | Molecular Cancer Therapeutics. 2016; 15(7): 1427 | | [Pubmed] | [DOI] | | | 196 |
Heart failure and chemotherapeutic agents |
|
| Susan Piper, Theresa McDonagh | | Future Cardiology. 2015; 11(4): 453 | | [Pubmed] | [DOI] | |
|
 |
|
|
|
Search Pubmed for